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Plasma membrane calcium (Ca2+) ATPase isoforms (PMCA1-4) extrude cytoplasmic free calcium 
([Ca2+]CYT) and maintain low intracellular Ca
2+ levels. Because [Ca2+]CYT increases can trigger cell 
death, inhibition of PMCA-mediated Ca2+ efflux has been proposed as a therapeutic strategy to kill 
breast cancer cells. The principal aim of this thesis was to characterise, by silencing techniques, 
PMCA isoforms and their effects on [Ca2+]CYT signals and cell death responses in the MDA-MB-231 
breast cancer cell line. These studies were performed in human MDA-MB-231 breast cancer cells, a 
widely studied model of basal-like breast cancer subtypes, that express the PMCA isoforms PMCA1, 
PMCA4 and PMCA2.  
For the measurement of cell death, changes in nuclear morphology (Hoechst 33342 fluorescence) and 
plasma membrane integrity (propidium iodide fluorescence) were assessed in MDA-MB-231 cells 
using ionomycin (Ca2+ ionophore), and ABT-263 (B-cell lymphoma-2 (Bcl-2) inhibitor) to activate 
caspase-independent and caspase-dependent cell death pathways, respectively. The consequences of 
PMCA1 or PMCA4 silencing on cell death, along with their effects on [Ca2+]CYT and nuclear factor 
kappa-B (NFκB) nuclear translocation were evaluated. Initial studies demonstrated that in the absence 
of a stimulus neither PMCA1 nor PMCA4 silencing altered cell viability. PMCA1 knockdown, 
however, potentiated ionomycin (caspase-independent)-induced cell death and augmented global 
[Ca2+]CYT signals generated with various Ca
2+ mobilising agents. On the contrary, PMCA4 silencing 
promoted ABT-263 (caspase-dependent)-induced cell death, independent of global [Ca2+]CYT 
signalling. Assessment of NFκB nuclear translocation showed that PMCA4 knockdown, but not 
PMCA1 silencing, attenuated transcription factor activity. The ability for the NFκB inhibitor IMD-
0354 to phenocopy the effect of PMCA4 siRNA on the promotion of ABT-263 cell death was also 
demonstrated. This data support diversity amongst PMCA isoforms expressed in the same cell, 
identifying differential roles for PMCA1 and PMCA4 in the regulation of Ca2+ signals and cell death 
responses in the MDA-MB-231 breast cancer cell line. 
Additional experiments examined in more detail, PMCA1-mediated regulation of global [Ca2+]CYT 
generated by different GPCR activators and the potential for SERCA (sarco/endoplasmic reticulum 
Ca2+ ATPase) activity to compensate for PMCA1 knockdown. These experiments showed that 
PMCA1 siRNA has distinct effects on ATP, compared with trypsin-induced Ca2+ responses. As a 
potential mechanism to explain why trypsin-mediated Ca2+ responses, compared with those of ATP 
are not altered by PMCA1 silencing, the potential contribution of SERCA activity was assessed using 
the SERCA inhibitor cyclopiazonic acid (CPA). PMCA4 silencing or CPA alone did not alter the 
shape of trypsin or ATP Ca2+ responses. In combination, PMCA1 siRNA and CPA delayed trypsin-
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mediated Ca2+ clearance. These results indicate that the calcium pumps, PMCA1 and SERCA, 
expressed in the same cell, can differentially contribute to Ca2+ clearance depending on the identity 
of the GPCR activated.  
PMCA2 overexpression in some breast cancers, and a report that recombinant PMCA2 
overexpression protects T47D breast cancer cells from Ca2+-induced (ionomycin) cell death suggests 
that this particular PMCA isoform may be a therapeutic target for the treatment of some breast 
cancers. To examine PMCA2 inhibition as a therapeutic strategy, the consequences of PMCA2 
siRNA on global [Ca2+]CYT signals and cell death responses were characterised in MDA-MB-231 
cells. [Ca2+]CYT signals generated with various agents demonstrated that endogenously expressed 
PMCA2 does not play a major role in global Ca2+ signalling. PMCA2 silencing alone produced no 
change in cell viability. The effect of PMCA2 siRNA on cell death was then measured in response to 
ionomycin or ABT-263. PMCA2 silencing did not significantly alter ionomycin-induced cell death, 
but potentiated ABT-263-induced apoptosis. These studies provide evidence that PMCA2 inhibition 
may sensitise some breast cancer subtypes to apoptosis initiated through Bcl-2 inhibition. 
Another calcium transporter that may be critical in regulating MDA-MB-231 cell death is the 
mitochondrial Ca2+ uniporter (MCU), which facilitates mitochondrial Ca2+ uptake. Molecular 
identification of MCU made it possible to extend these thesis studies and examine MCU distribution 
in clinical breast cancers. MCU levels were elevated in the oestrogen receptor-negative and basal-
like subtypes of breast cancer. The significance of this elevation was addressed by down-regulating 
MCU expression in MDA-MB-231 cells and assessing the functional consequence on proliferation, 
cell death and [Ca2+]CYT signals. MCU siRNA produced no change in proliferation and had no effect 
on cell viability. Cell death initiated with ABT-263 was not altered by MCU silencing. MCU down-
regulation, however, acted as a sensitiser of cell death triggered by ionomycin. Assessment of 
[Ca2+]CYT signals indicates that MCU siRNA-mediated regulation of ionomycin-mediated cell death, 
in contrast with the PMCA1 silencing studies, occurs without effects on global [Ca2+]CYT signals. 
In summary, breast cancer death responses are modulated by isoform-specific PMCA or MCU 
knockdown. Inhibitors of PMCA1 or MCU may sensitise some breast tumors to cancer therapies that 
activate caspase-independent cell death. Alternatively, specific inhibitors of PMCA4 or PMCA2 may 
have therapeutic potential in sensitising some aggressive breast tumors, to cancer therapies that work 
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Chapter 1 Literature Review 
1.1 Calcium Homeostasis 
1.1.1 Introduction 
Free ionised calcium (Ca2+) is present in every eukaryotic cell and has an essential second messenger 
function. Many stimuli including membrane depolarisation, stretch, noxious agents, and hormones 
transiently increase cytoplasmic Ca2+ levels ([Ca2+]CYT) [1, 2]. This increase in [Ca
2+]CYT acts as a 
signal, decoded by the cell into a myriad of events [1, 2] ranging from synaptic transmission [3] 
through to the regulation of life and death [4]. Regulating such a plethora of physiological processes, 
however, is conditional on the shape of a Ca2+ signal [1, 2] including parameters such as the duration 
and amplitude. The distribution of Ca2+ between cell compartments such as the mitochondria and 
endoplasmic reticulum [1, 2] is also significant. High magnitude Ca2+ levels, for example, is 
characteristic of the endoplasmic reticulum Ca2+ store [5], whereas high magnitude Ca2+ increases 
can trigger cell death in the cytoplasm [6].  
“Ca2+ signalling toolkit” [2] is a term coined by Berridge et al., which describes the wide variety of 
Ca2+ signalling proteins utilised by cells to process Ca2+ transients into specific shapes and sizes. 
Calcium transport proteins such as ion channels, pumps and exchangers are important components of 
the “Ca2+ signalling toolkit”, and coordinate Ca2+ signals by controlling Ca2+ flux across lipid 
membranes [1, 2]. Calcium transport proteins are heterogeneously expressed, and thus divide the Ca2+ 
signal into distinct compartments including the cytoplasm, endoplasmic reticulum, mitochondria and 
the Golgi apparatus [1, 2]. Figure 1-1 illustrates some Ca2+ transporters located at the cell surface and 
on the membrane encasing the endoplasmic reticulum [7]. Described herein are some of the key Ca2+ 






Solid arrows indicate the direction of Ca2+ flux. Light blue shapes represent examples of endogenous 
activators for the specific Ca2+ transport proteins. This figure does not provide an accurate 
interpretation of ion stoichiometry or of the exact domains for the example Ca2+ transport proteins 
shown. Plasma membrane ion channels permeable to Ca2+ allow Ca2+ influx [1, 2]. The example is a 
voltage-gated Ca2+ channel subunit α1, which mediates L-Type Ca2+ currents as a functional multimer 
in response to membrane depolarisation [8]. Store release of Ca2+ requires receptor activation at the 
plasma membrane [1, 2]. The muscarinic receptor shown, is a GPCR protein linked to the PLC 
transduction pathway [9]. Acetylcholine binds to the extracellular face of the muscarinic receptor and 
mobilises cytosolic IP3, which engages the ligand-gated Ca
2+ channel, IP3R (in multimeric form) to 
release the Ca2+ store within the ER [1, 2, 9]. PAR is another GPCR protein linked to the PLC 
transduction pathway [10, 11]. Proteolytic cleavage of the extracellular N terminus activates PAR 
[10, 11]. Depicted as scissors, an example protease that activates PAR is trypsin [10, 11]. Pumps and 
exchangers mediate Ca2+ efflux [1, 2]. The exchanger, NCX1 removes Ca2+ from the cell in exchange 
for Na+ influx [12]. SERCA is another Ca2+ efflux pump, but its position on the ER refills the 
intracellular Ca2+ store [1, 2]. PMCA4 is also a Ca2+ efflux pump [1, 2] that is activated by acidic 
phospholipids and calmodulin [13]. Store-operated Ca2+ entry is the response to depletion of stored 
Ca2+ inside the ER [14]. The broken arrow indicates the translocation path of STIM1 dimers [15, 16] 
to regions adjacent the ER and Orai [17, 18]. STIM1 dimers activate the flux of Ca2+ through Orai 
channels, which are functional as tetramers and specifically replenish ER Ca2+ [19, 20]. Figure 
adapted from a review article [21]. 
 
  
Figure 1-1: Integral Ca2+ transport proteins found on the ER and plasma membranes. 
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1.1.2 Cytoplasmic calcium levels ([Ca2+]CYT) 
In an unstimulated cell, [Ca2+]CYT is maintained at a low concentration of approximately 100 nM [1, 
2]. To initiate a signalling event, free ionic Ca2+ must cross impermeable cell membranes, and rapidly 
accumulate in the cytoplasm to concentrations of up to 1 µM, before the signal is terminated by Ca2+ 
efflux mechanisms [1, 2]. Figure 1-2A is an example Ca2+ transient typical of the cytoplasm. The 
extracellular medium and the endoplasmic reticulum, because they contain high Ca2+ concentrations 
are Ca2+ reservoirs to increase [Ca2+]CYT [1, 2]. Although thermodynamically favoured by the 
electrochemical gradient, Ca2+ entry depends on the activation of Ca2+ permeable ion channels, 
embedded within the plasma and endoplasmic reticulum membranes [1, 2]. Ion channels are classified 
according to their mode of activation; examples are the voltage-gated and ligand-gated Ca2+ channels, 
which are activated by membrane depolarisation and specific ligand binding, respectively [1, 2]. 
Shown in Figure 1-1 are the two discrete pathways, Ca2+ influx and Ca2+ store release, in which ion 
channels achieve [Ca2+]CYT increases. 
1.1.2.1 Calcium influx 
Ca2+ influx is Ca2+ entry directly from the extracellular medium into the cytoplasm through Ca2+-
permeable ion channels in the plasma membrane. Voltage-gated Ca2+ channels are sub-divided into 
L-, N-, P-, Q-, R- and T-type, and are different in their Ca2+ conductivity [8]. The α1 channel subunit 
that mediates L-type channel currents is depicted in Figure 1-1 [8]. Calcium influx is the principal 
route of Ca2+ entry in excitable cells, supporting processes like synaptic transmission — where ion 
channels open in response to membrane depolarisation, switch on Ca2+ influx and encode events like 




1.1.2.2 Calcium store release  
In contrast to the direct nature of Ca2+ influx, Ca2+ store release involves the redistribution of Ca2+ 
sequestered inside the endoplasmic reticulum into the cytoplasm via the recruitment of an 
intracellular protein, phospholipase C (PLC) [1, 2]. Ca2+ store release is shown schematically in 
Figure 1-1. This pathway relies on activation of plasma membrane receptors, such as G-protein 
coupled receptors (GPCRs), which are coupled to the PLC signal transduction pathway [1, 2]. As a 
consequence of PLC activation, the minor membrane phospholipid, phosphatidylinositol 4,5-
bisphosphate (PIP2) is hydrolysed into inositol (1,4,5) triphosphate (IP3) [23]. IP3 engages the Ca
2+-
permeable ion channel inositol triphosphate receptor (IP3R), positioned on the endoplasmic reticulum 
membrane. IP3R activation releases Ca
2+ stores and rapidly increases [Ca2+]CYT up to sub-µM levels 
[24]. The example in Figure 1-1 is agonist activation of muscarinic receptors, where the endogenous 
agonist acetylcholine binds to the muscarinic receptor, activates the PLC signal transduction pathway, 
and increases [Ca2+]CYT [9]. This  [Ca
2+]CYT increase is then decoded into an event like smooth muscle 
contraction [9].  
While most GPCR receptors are reversibly activated by agonists, the subfamily of GPCRs known as 
proteinase activated receptors (PARs) are irreversibly activated by proteolytic cleavage [10, 11]. 
Figure 1-1 depicts trypsin (a protease)-mediated cleavage of PAR, which exposes an N-terminal 
domain that activates this receptor, via intramolecular binding to produce a cell response [10, 11].  
1.1.2.3 Calcium efflux 
Ca2+ efflux mechanisms, in addition to the maintenance of low cytoplasmic Ca2+ levels, also 
participate in terminating Ca2+ transients, and therefore shape calcium signals, particularly the decay 
phase [1, 2]. Equipped with a combination of Ca2+ pumps and exchangers, the cell meets the 
requirements for Ca2+ efflux against unfavourable electrochemical gradients [1, 2]. Figure 1-1 
highlights the Ca2+ efflux mechanisms, sodium (Na+)-Ca2+ exchanger (NCX), the sarcoplasmic-
endoplasmic reticulum Ca2+ ATPase (SERCA) and the plasma membrane Ca2+ ATPase (PMCA) 




1.1.2.4 Sodium-calcium exchanger (NCX) 
Located at the plasma membrane, the sodium-calcium exchanger (NCX) transports Na+ ions into the 
cell along its electrochemical gradient in exchange for Ca2+ ions, which are removed from the 
cytoplasm against the electrochemical gradient [12]. The direction of the NCX is reversible under 
conditions of high intracellular Na+ levels [12]. Low intracellular Na+ levels, however, almost always 
favour Ca2+ efflux [12]. NCX1 is illustrated in Figure 1-1 and is the most extensively studied NCX 
isoform. NCX1 has an affinity for Ca2+ in the low µM range, extruding Ca2+ most effectively from a 
stimulated cell, when the magnitude of [Ca2+]CYT is well above resting levels [12]. 
1.1.2.5 Sarcoplasmic-endoplasmic reticulum calcium ATPase (SERCA) 
Positioned on the ER membrane (Figure 1-1), the SERCA pump facilitates Ca2+ transport from the 
cytoplasm into the ER lumen, which terminates [Ca2+]CYT transients and refills the endoplasmic 
reticulum Ca2+ store [12]. SERCA contains a catalytic domain that hydrolyses adenosine-5'-
triphosphate (ATP) into adenosine diphosphate (ADP) [25], providing the energy necessary to 
actively transport Ca2+ into the ER [1, 2]. The SERCA pump is a high affinity, low capacity Ca2+ 
transporter, therefore transporting Ca2+ in the absence or presence of a Ca2+ mobilising stimulus, 
maintaining basal [Ca2+]CYT and terminating Ca
2+ signals [1, 2]. 
1.1.2.6 Plasma membrane calcium ATPase (PMCA) 
PMCA calcium pumps share some structural similarities with the SERCA pump [26].  This includes 
the presence of an intracellular catalytic domain that supports active Ca2+ transport through ATP 
hydrolyses [1, 2, 27]. Similar to the NCX, PMCA pumps are also situated on the plasma membrane 
(Figure 1-1), and extrude cytoplasmic Ca2+ from the cell [1, 2]. Endogenous activators of the PMCA 
pump include the Ca2+-sensing protein, calmodulin and acidic phospholipids [13, 28]. Both activate 
PMCA by increasing the maximum velocity of the pump, and reducing its affinity for Ca2+ from 10-




1.1.3 Endoplasmic reticulum calcium levels ([Ca2+]ER) 
For many Ca2+ signals, including those coupled to IP3 signal transduction (section 1.1.2.2, page 5), 
the endoplasmic reticulum (ER) is the most important intracellular Ca2+ store released in the presence 
of a stimulus [1, 2]. Redistribution of Ca2+ from the ER to the cytoplasm, not only fuels a [Ca2+]CYT 
increases, but simultaneously depletes ER Ca2+ levels ([Ca2+]ER). This depletion activates a phase of 
Ca2+ entry that restores high magnitude [Ca2+]ER concentrations. Maintaining [Ca
2+]ER up to 1 mM 
[5] is required for future Ca2+ signalling events, but also supports organelle specific functions such 
as vesicle trafficking, regulation of cholesterol metabolism and protein folding/processing [29]. 
Figure 1-2 shows the changes in [Ca2+]ER expected during IP3-mediated calcium signals. The ER Ca
2+ 
content is refilled by a mechanism initially proposed by James Putney in 1986 and known as store-
operated Ca2+ entry (SOCE) [14]. 
1.1.3.1 Store operated calcium entry 
Triggered by ER store depletion, store operated calcium entry (SOCE) activates ion channels at the 
plasma membrane, resulting in Ca2+ entry from the extracellular medium into the ER [14]. Reviewed 
by Varnai et al. [20], the specific proteins mediating SOCE were recently identified as stromal 
interaction molecule (STIM) and Orai channels. Briefly, at high [Ca2+]ER concentrations STIM1 binds 
to Ca2+ inside the ER lumen [15, 16]. At low [Ca2+]ER concentrations, however, when the intracellular 
store is depleted during a Ca2+ signalling event, STIM1 dissociates from Ca2+ and binds to another 
STIM1 monomer [15, 16]. The resulting STIM1 oligomers, translocate to the plasma membrane in 
domains adjacent the ER [15, 17, 18], activate Ca2+ entry though Orai channels, and replenish 
intracellular ER Ca2+ stores [19]. The Orai1 subunit, depicted in Figure 1-1, is functional as a 




1.1.4 Mitochondrial calcium levels ([Ca2+]MIT) 
In 1992 a mitochondrial-targeted aequorin construct enabled research laboratories to directly monitor 
mitochondria Ca2+ levels ([Ca2+]MIT) using luminescence [30]. This technique confirmed that 
mitochondria are not spectators of calcium signals, but they can rapidly accumulate Ca2+ and 
experience [Ca2+]MIT increases in parallel with [Ca
2+]CYT increases [30, 31]. Figure 1-2 illustrates a 
typical Ca2+ signal that mitochondria experience in a stimulated cell.  
Mitochondria Ca2+ uptake occurs through the low affinity, high capacity mitochondrial uniporter [32, 
33], which is thermodynamically driven by an electrochemical gradient generated by oxidative 
metabolism [34]. Using the mitochondrial-targeted aequorin construct, [Ca2+]MIT levels are reported 
to be up to concentrations of 5 µM or even 500 µM in some cell types [30, 35]. These values, which 
can exceed the magnitude of [Ca2+]CYT signals, are surprising because experiments in isolated 
mitochondria report that MCU has a low Ca2+ affinity [34]. This anomaly was resolved by the 
microdomain hypothesis and the molecular identification of the components responsible for flux of 
Ca2+ ions across mitochondrial membranes as described below. 
1.1.4.1 The microdomain hypothesis 
The microdomain hypothesis acknowledges the ability for a cell to unevenly distribute Ca2+ 
throughout the cytoplasm, where the Ca2+ level in a microdomain can greatly exceed the level of 
[Ca2+]CYT measured in the bulk cytoplasm [36]. Strategic placement of mitochondria in close 
proximity to the ER directly exposes the MCU to IP3R Ca
2+ release sites [37]. Consequently, despite 
a low Ca2+ affinity, during cell stimulation  the  mitochondrial calcium uniporter rapidly transports 
Ca2+ into the mitochondria matrix at magnitudes [38] that can surpass [Ca2+]CYT levels. 
1.1.4.2 The Mitochondrial Calcium Uniporter (MCU) 
Although mitochondrial Ca2+ uptake is known to regulate numerous cell events [39] such as 
catecholamine secretion [35], apoptosis [40] and oxidative metabolism for ATP synthesis [41], the 
molecular identity of this calcium transporter remained unknown until 2011. Two research 
laboratories independently identified the pore-forming subunit of the MCU as CCDC109A [32, 33]. 
This discovery now allows scientists to  assess the significance of mitochondria Ca2+ uptake  by 






In the presence of a stimulus, intracellular Ca2+ is unevenly distributed throughout the various cell 
compartments [1, 43]: (A) the cytoplasm experiences a transient increase in Ca2+ [1, 43] (B) the ER 
Ca2+ content rapidly decreases due to store release of Ca2+ [1, 5, 43] and (C) a subpopulation of 














A wide-variety of Ca2+ transport proteins, including ion-channels and pumps work in concert to 
process Ca2+ into unique signals, which is then decoded into specific cell events. One calcium 
transporter, PMCA contributes to calcium homeostasis via Ca2+ efflux. As discussed in the next 
section, PMCA is a very large family of proteins that are extremely diverse in their structure, and 
regulation at the molecular level.  This advocates that PMCA calcium pumps, beyond simple Ca2+ 




1.2 The Plasma Membrane Calcium ATPase (PMCA) 
1.2.1 Introduction 
Originally discovered in 1966 by Schatzmann [44], Plasma Membrane Calcium ATPase (PMCA) 
pumps consist of four isoforms (PMCA1-4), encoded by separate genes (ATP2B1-4) [45-48] that are 
subject to alternative splicing, which yields over thirty splice variants [49]. With so many variants, 
PMCAs are predicted to accomplish many unique tasks throughout the body. This prediction is the 
natural consequence of PMCA diversity at the molecular level, which will now be discussed.  
1.2.2 Molecular structure 
PMCA pumps are members of the P-Type ATPase family, which actively pump cations across cell 
membranes [50]. The SERCA pump (introduced in section 1.1.2.5, page 6) is also a member of the 
P-Type ATPase family that actively transports Ca2+ [27]. The crystal structure of the SERCA pump 
[25] provides the basis for the structure and mechanism of ATP driven transport [27]. Four domains 
are conserved amongst the P-Type ATPases, they are a phosphorylation domain (P-domain), a 
nucleotide binding domain (N-domain), an actuator domain (A-domain) and a membrane domain (M-
domain) [27]. Figure 1-3 highlights these domains within the structure of PMCA. The P-domain is 
the catalytic core that contains the signature motif DKTGILT [27], which harbours the characteristic 
aspartyl phosphate residue [25]. The N-domain, divides the P-domain and contains a lysine (K) 
residue important for the binding of the nucleotide, ATP [25, 27]. The discontinuous A-domain 
contains the TGE sequence [25] that interacts with the aspartyl phosphate residue during pump 
activity [27]. The M-domain is composed of ten hydrophobic transmembrane regions and is the least 
conserved region amongst the P-type ATPase family [27]. A comprehensive review of P-type ATPase 
structure and mechanism is given elsewhere [27]. In addition to features common to P-type ATPases, 
PMCA also contains two alternative splice sites and a very long intracellular carboxy-terminal region, 
containing motifs essential for the biochemical regulation of the pump within an intact cell [50]. The 






PMCA is a P-Type ATPase pump, responsible for the efflux of cytoplasmic Ca2+ from the cell [50]. 
PMCA shares structural features with the SERCA pump [26]. There are four domains, indicated by 
different colours, that are predicted by the crystal structure of the SERCA pump [25] and the circle 
depicts the ATP binding site [51]. The P-domain (orange) is the catalytic core and contains the 
characteristic phosphoryl-aspartate, D [25]. The N-domain (light blue) contains the signature, lysine 
(K) residue, which is important for the binding of ATP [25, 27]. Alternative splicing increases the 
molecular diversity amongst the PMCA pumps [49]. The A-domain (pink) contains the alternative 
splicing site A [49]. The cytoplasmic, C-terminus (green) contains the alternative splicing site C, 
which overlaps with the major regulatory region of the pump [49, 52] The M-domain (navy blue) is 
indicated by the hydrophobic transmembrane spanning regions numbered 1-10 [27]. Figure adapted 








1.2.3 Alternative splicing 
Alternative RNA splicing describes the process whereby an mRNA precursor is spliced more than 
one way during mRNA maturation, producing many different proteins encoded by the same gene 
[53]. Alternative splicing and its regulation have been reviewed by Black et al [53]. All PMCA 
isoforms contain two sites that undergo alternative RNA splicing (Figure 1-3), these splice sites are 
known as splice site A and splice site C [49, 52, 54]. Because the variable insertion of exons at splice 
site A and C produces different primary structures, each PMCA splice variant is predicted to adopt a 
distinct overall three-dimensional conformation, with unique regulatory properties [49, 55]. This 
phenomenon has led to the discovery of over thirty human PMCA variants, which contribute to Ca2+ 
homeostasis throughout the body [49]. 
1.2.3.1 Splice site A 
Splice site A is positioned within the A-domain of PMCA, and involves the variable insertion of up 
to three exons to produce the w, x and z variants [49]. Very little is known about the functional role 
of alternative splicing at site A. Studies of the w variant demonstrate that targeting of PMCA2w to 
the apical membrane of cells, independent of the configuration at splice site C [56]. This was initially 
demonstrated using confocal fluorescence microscopy in polarised Madin-Darby canine kidney cells 
overexpressing PMCA2w [56]. Consistent with this finding, another study reported that endogenous 
PMCA2w is targeted to hair bundles in rat hair cells [57]. The apical nature of the PMCA2w variant 
was also confirmed by Reinhardt et al. in mouse mammary gland epithelial cells [58, 59]. Endogenous 
PMCA2bw, the splice variant upregulated during lactation, is targeted to the apical membrane for a 





1.2.3.2 Splice site C 
Splice site C is located at the C-terminus of PMCA and involves either the exclusion or inclusion of 
one exon [52]. The exclusion of the exon results in the full length PMCAb variants, whereas including 
the exon shifts the translational reading frame, producing the truncated PMCAa variants [52]. The C 
splice site overlaps with a key regulatory region positioned in the C-terminus of the pump, containing 
the calmodulin binding domain [60], which mediates calmodulin-induced pump activation [61]. 
Alternative splicing at site C, which alters the regulatory region, significantly increases PMCA pump 
diversity [49, 55].  
1.2.4 Biochemical regulation of PMCAs 
Biochemical regulation controls the trafficking, functional and degradation properties of proteins 
[62]. This involves interactions with intracellular proteins through direct protein-protein binding or 
by chemical modification of amino acids within specific motifs [62]. Primary structure analysis of 
PMCA reveals several key motifs, concentrated within the C-terminal end of the pump and 
responsible for its biochemical regulation [50]. The sequence alignment between the C-terminus of 
the PMCA isoforms and splice variants, shown in Figure 1-4, reinforces sequence diversity amongst 
the pumps in this region. 
1.2.4.1 Auto-inhibition 
Auto-inhibition describes the conformation that PMCA adopts in the resting cell, which involves the 
intra-molecular binding of internal ‘receptors sites’ [63-65]. These receptor sites are positioned within 
the C-terminal tail [63], the catalytic domain [64] and the A-domain [65] of the pump. This 
conformation excludes substrates, like ATP from accessing catalytic sites and restricts pump activity 
in the resting cell, and [Ca2+]CYT is low [63-65]. During cell stimulation, when [Ca
2+]CYT is transiently 
elevated, calmodulin binds to PMCA within the calmodulin binding domain, displaces auto-inhibition 
and activates the pump [63-65]. The calmodulin binding domain,  highlighted in Figure 1-4, is located 
in the C-terminus of PMCA [60]. The basal activity and affinity for calmodulin are widely varied 
amongst the PMCA isoforms and their splice variants [50]. PMCA2 has higher basal activity and is 
more sensitive to calmodulin compared with other PMCA isoforms [66], independent of the 
configuration at splice site C [67]. However, sequence variation from alternative splicing at site C in 
PMCA4 [68, 69] results in the short variant, PMCA4a having a higher basal activity and a reduced 





The linear amino acid sequences for human PMCA variants were obtained from the National Centre 
for Biotechnology Information (NCBI) protein database. The cytoplasmic C-terminal portion of 
PMCA variants were aligned using the ClustalW2 algorithm. Several sequence motifs are 
concentrated within this region of the pump and are responsible for its biochemical regulation [50]; 
they are highlighted in the sequence alignment. The calmodulin binding domain mediates 
calmodulin-induced pump activation [13, 28]. The consensus site for caspase-3 cleavage regulates 
pump activity during apoptosis [72-76]. Residues phosphorylated by PKA [77, 78], PKC [79, 80] and 
FAK [81] are illustrated (triangles). A potential ER retention signal has been reported upstream of 
the calmodulin binding domain [82], which could be important regulatory property of the pump 
during apoptosis [76]. A PDZ binding domain is only found in the full length PMCA variants [83].  
 
 
Figure 1-4: Sequence alignment of the cytoplasmic C-terminal end of some PMCA variants.  
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1.2.4.2 Phosphorylation of PMCAs 
Phosphorylation is a chemical modification, involving the covalent addition of a phosphate group to 
a single amino acid residue within a specific motif [62]. Phosphorylation alters protein function 
through a conformational change or by facilitating interactions with other intracellular proteins, 
driving the formation of larger protein complexes [62]. Protein kinases catalyse the phosphorylation 
reaction and include protein kinase A (PKA), protein kinase C (PKC) and focal adhesion kinase 
(FAK). Figure 1-4 highlights the PKA, PKC and FAK phosphorylation sites reported within the C-
terminus of some PMCA pumps. However, not all PMCA pumps contain these sites; therefore, 
PMCA variants exhibit differences in PKA, PKC and FAK-mediated regulation.  
PKA-mediated phosphorylation of the serine (S) residue, downstream of the calmodulin binding 
domain, within the motif KRNSS, is only reported for PMCA1, and activates this pump isoform [77, 
78]. Within the calmodulin binding domain of PMCA, both S and threonine (T) residues are subject 
to PKC-mediated phosphorylation [79, 80, 84]; and this modification can activate [85] or inhibit 
PMCA4b [80], modestly inhibit PMCA2a or PMCA3a [86], while PMCA4a is unaffected [87, 88]. 
FAK-mediated phosphorylation of a tyrosine (Y) residue, within the motif EVTPY is downstream of 
the calmodulin binding domain and inhibits PMCA4b activity [81, 89]. The functional consequence 
of this chemical modification, triggered by thrombin has been examined in  platelets [90]. Inhibition 
of PMCA4b-mediated Ca2+efflux increases intracellular Ca2+ levels, and activates platelet 
aggregation [90]. Inhibition of PMCA-mediated Ca2+ efflux by FAK, augments intracellular Ca2+, 





1.2.4.3 PDZ binding domain of PMCAs  
PDZ domains were initially discovered in three proteins; post synaptic density protein (PSD95), 
Drosophila disc large tumor suppressor (DlgA), and zonula occludens-1 protein (zo-1), which is 
reflected in the acronym PDZ [93]. The longer PMCAb splice variants, but not the shorter PMCAa 
variants, contain a conserved PDZ binding domain ETS(L/V) at the C-terminal end [83]. The 
sequence alignment in Figure 1-4 highlights the PDZ binding domain in the full length pump variants. 
The PDZ binding domain allows some PMCA variants to bind partner proteins with a PDZ domain, 
which can drive the formation of multiprotein scaffolds and support local signal transduction at the 
plasma membrane [93]. Kim et al were the first to demonstrate the binding of PMCA4 to members 
of the membrane-associated guanylate kinase (MAGUK) protein family through PDZ domains [83]. 
Since this first account, PMCA4b has been shown to interact with the important mediator, neuronal 
nitric oxide synthase-1 (nNOS-1) through its PDZ domain [94]. nNOS-1 is a calmodulin regulated 
protein that converts L-arginine into nitric oxide (NO) in the presence of Ca2+ [95]. PMCA and nNOS 
are both targeted to sub-cellular domains within cavaolae [95, 96] and associate via the PDZ domain 
of nNOS [94] to form a scaffold for local signal transduction. PMCA4b negatively regulates nNOS 
by reducing the local Ca2+ concentration, inhibiting NO production. The physiological consequence 
of this PDZ-mediated interaction was explored in transgenic mice overexpressing PMCA4b, reducing 
heart contractility [97] and increasing vascular tone [98].  
1.2.4.4 Proteolytic cleavage of PMCAs 
Another layer of protein regulation is proteolysis, whereby proteases act like molecular scissors by 
cutting proteins irreversibly within specific consensus sites to fragment proteins to alter their activity 
and/or location [62]. Calpain and caspases are two families of proteases that cleave PMCA, within or 
in close proximity to the calmodulin binding domain [50]. Cleavage of PMCA truncates the pump 
and removes downstream regulatory sequences, affecting the calmodulin binding domain, the 





There are two isoforms of calpains, µ and m that are activated by micromolar and millimolar 
concentrations of Ca2+, respectively [99]. PMCA is cleaved and truncated by calpain to irreversibly 
activate the pump in isolated membrane preparations [100, 101]. This provides another mechanism 
for pump activation, in addition to calmodulin and acidic phospholipids [13, 28]. PMCA is likely to 
be regulated by calpains in a variety of cell signalling pathways because calpain activity is controlled 
by the ubiquitous second messenger, Ca2+ [99]. The precise role of these proteases, although unclear, 
have been implicated in the cell death pathways, including apoptosis and necrosis [99] 
 Caspases  
Caspases are proteases employed during apoptosis to dismantle cell components for subsequent 
elimination [72]. They are subdivided into ‘initiator’ and ‘effector’ caspases to distinguish those that 
initiate (caspase-8, -9, -10) and execute (caspase-3,-6,-7) apoptosis [72]. The initiator caspases are 
activated by homodimerisation on specialised platforms, formed when a cell receives an apoptotic 
signal [72, 102]. Initiator caspases, once stimulated recruit, cleave and activate the executioner 
caspases [72]. Active executioner caspases cleave target substrates at the preferred consensus motif 
DEV(D/G) [72]. This motif in the C-terminus of the PMCA isoforms is highlighted in Figure 1-4. A 
review by Earnshaw et al. provides further details on caspase structure, activation, substrates and 
function during apoptosis [72]. Patzy et al. provided the first report that PMCA4b is cleaved by 
caspase-3 in cells undergoing staurosporine-induced apoptosis, at the consensus site DEID, upstream 
of the calmodulin binding domain [75]. This provides a potential link between PMCAs and apoptosis, 





1.2.5 Tissue distribution of PMCAs 
The tissue distribution of PMCA isoforms has been demonstrated at the level of messenger 
ribonucleic acid (mRNA) [49] and protein [103]. PMCA1 and PMCA4 are expressed ubiquitously 
throughout the body, while PMCA2 and PMCA3 show a restricted tissue distribution within excitable 
tissues [49]. PMCA1 is concentrated in the brain, lung and intestine [104], whereas PMCA4 is the 
predominate isoform expressed in erythrocytes [103] and spermatozoa [105]. PMCA2 is abundantly 
detected within the cerebellum and cerebral cortex [103] and in the hair cells of the inner ear [106]; 
while a large quantity of PMCA3 is detected in the choroid plexus [103]. Specific PMCA isoforms 
can also be transiently expressed in tissues to perform specialised functions. An example of this is 
upregulation of PMCA2 in the lactating mammary gland [58, 107, 108]. Reinhardt et al. have shown 
that PMCA2 upregulation, parallels increased milk production and is the predominate isoform in the 
lactating mammary gland [58, 108]. Conversely, when lactation ends and milk production is no longer 
required, PMCA2 is abruptly downregulated during mammary gland involution [107]. 
1.2.6 Physiological roles of PMCAs 
The contribution of individual PMCA isoforms to Ca2+ homeostasis and cell function is not well 
understood due to the lack of specific PMCA inhibitors. However, the development of PMCA 
knockout animals [109], and the identification of PMCA genetic mutations [110] has provided insight 
towards understanding the isoform specific functions of different PMCA isoforms. No genetic 
mutations have been reported for PMCA1, and mice null for the PMCA1 gene do not survive [111].  
This is consistent with the housekeeping function if this isoform, where PMCA1-mediated Ca2+ efflux 
is essential in maintaining the low intracellular Ca2+ levels required for Ca2+ homeostasis [111]. 
PMCA4 null mice are viable and, except for male infertility appear healthy [112]. Male infertility, in 
this context, is the consequence of impaired sperm motility upon the deletion of PMCA4 [105]. 
Genetic mutations and knockout animals have been described for PMCA2. PMCA2 null mice 
survive, but have compromised vestibular and auditory systems that manifests as deafness and 
difficulties in maintaining balance [113]. The deafwaddler mouse encodes a mutant PMCA2 gene 
that reduces pump activity by 70% [114, 115]. These mice are deaf and display vestibular/motor 
imbalance [114, 115]. The Wriggle Mouse Sagami is another example of a genetic PMCA2 mutation, 
and is associated with hereditary hearing loss [116]. Reinhardt et al. used a PMCA2 null mouse model 
to study PMCA2 in lactating rodents. Consistent with PMCA2 upregulation in the lactating mammary 
gland [58, 108], PMCA2-null mice produce milk with significantly reduced Ca2+ concentration [59]. 
Although PMCA3 null mice have not been reported, genetic defects in PMCA3 have been 
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documented and affect neural pathologies, and is associated with the developmental delay, hypotonia, 
cerebellar ataxia [110].  
1.2.7 Regulation of calcium homeostasis by PMCAs 
The question still remains: how do the PMCA isoforms differentially modulate Ca2+ homeostasis and 
determine cell function? The answer is influenced by the different structural and regulatory properties 
amongst the pump isoforms. However, the majority of studies on PMCA use the purified pump or 
isolated membrane preparations, lacking the physiological regulators that determine pump activity in 
vivo. A study by Brini et al. is important because intact Chinese hamster ovary (CHO) cells, which 
overexpress the full length pump variants (PMCA1-4b) were used to investigate the impact of PMCA 
isoforms on Ca2+ homeostasis [117]. In cells overexpressing specific PMCA isoforms, the [Ca2+]CYT 
and [Ca2+]MIT was significantly reduced upon ATP-induced release of the IP3-sensitve Ca
2+ stores, 
detected as reduced amplitude and shorter duration of the Ca2+ signal [117]. The authors attributed 
this observation to a reduced basal [Ca2+]ER; where a small change in [Ca
2+]ER significantly reduced 
the level of Ca2+ redistributed into the cytoplasm or mitochondria upon Ca2+ store release [117]. This 
effect was more pronounced for the non-ubiquitous pump isoforms, PMCA2 and PMCA3 and is 
consistent with their abnormally high affinity for Ca2+ determined in isolated membrane preparations 
[66]. These results are also consistent with the restricted tissue distribution of PMCA2 and PMCA3, 
which are highly expressed in excitable cells that frequently experience large Ca2+ fluxes and require 
a highly efficient Ca2+ efflux system [117].  
1.2.8 Summary 
PMCA isoforms have unique tissue distribution patterns and are subject to intense regulation at the 
level of expression, RNA processing, post-translational modification and interactions with 
intracellular proteins. Although the structure and biochemical properties of PMCA isoforms are well 
studied, the specific physiological functions of PMCA isoforms in intact cells are not as well defined. 
Cell death is one pathway where the shape and location of Ca2+ may be particularly important. 
Because Ca2+ efflux via PMCA calcium pumps can influence the shape and location of Ca2+ signals, 





1.3 Cell Death 
1.3.1 Introduction 
Cells are eliminated from the body by different cell death pathways, including apoptosis and necrosis 
[118]. Necrosis proceeds as uncontrolled cell death, involving tissue damage and is observed in the 
pathological setting of ischemic reperfusion injury, epilepsy, Alzheimer's disease and other 
inflammatory injuries [118]. Apoptosis is the contrast to necrosis, and proceeds as programmed cell 
death that physiologically regulates cell populations during embryologic development, 
metamorphosis and for regulation of tissue size [118]. Deregulation of the apoptotic program is 
characteristic of diseases such as cancer; where the tumour cell acquires resistance to apoptotic 
signals that would normally eliminate the cell [119]. This section will outline the morphological and 
biochemical hallmarks of apoptosis before delineating Ca2+ regulation of this signalling pathway. 
1.3.2 Morphological features 
Kerr et al. first documented apoptosis using an electron microscope in 1972 [120]. Morphologically 
apoptosis is visualised as the formation of apoptotic bodies that are observed as well-preserved, 
membrane bound compartments that originate from the whole cell [120]. The formation of apoptotic 
bodies is accompanied by the marked condensation of the cell involving chromatin condensation 
[121], membrane blebbing [122] and deoxyribonucleic acid (DNA) fragmentation [123]. During the 
late phase of apoptosis the newly formed apoptotic bodies are engulfed by neighbouring cells, 
followed by their intracellular degradation [120]. Apoptosis eliminates cells discretely, avoiding the 
release of intracellular contents into the extracellular medium, which would evoke widespread injury 




1.3.3 Biochemical hallmarks 
Since its first documentation [120], apoptosis has been under intense investigation. It is now widely 
accepted that underlying mechanisms include an elevation in ATP, activation of caspases and 
exposure of phosphatidylserine at the extracellular face of the plasma membrane [124]. Apoptosis is 
an active event, therefore increased ATP provides the energy to drive the process to completion [125, 
126]. Caspases, introduced in section 1.2.4.4.2, page 21, are the proteases that execute apoptosis [72]. 
Phosphatidyserine is an acidic phospholipid that is found within the inner leaflet of the plasma 
membrane and redistributes to the outer leaflet during apoptosis, serving as a recognition molecule 
for phagocytosis [127]. The signalling cascades that activate these biochemical changes to effect 
apoptosis are divided into intrinsic and extrinsic pathways [128]. Figure 1-5 illustrates these two 
discrete signalling cascades that result in apoptosis. 
1.3.3.1 Intrinsic apoptosis 
Apoptosis is the result of death signals like DNA damage, chemotherapeutic agents, serum starvation 
and UV radiation, and can be intrinsically controlled by the cell’s mitochondria [129]. The family of 
B-cell lymphoma 2 (Bcl-2) proteins receive and then deliver death inputs to the mitochondria [130]. 
Bcl-2 proteins are sub-divided into three groups and share sequence homology within four Bcl-2 
homology (BH) domains (BH1-BH4) [131]. The first group includes Bcl-2, which have an anti-
apoptotic function and contain up to four BH domains [131]. The second group are the pro-apoptotic 
members, BH3-only proteins that initiate the intrinsic cascade [129, 131]. The final group are also 
anti-apoptotic in nature but they contain multiple BH domains [131]. Bcl-2 proteins are reviewed by 
Thomadaki et al. [131]. Bak and Bax are members of the multiple BH domains subgroup and are 
activated by the upstream, BH3 proteins which register the death input [129]. When activated, Bax 
and Bak adopt a new conformation, undergo homo-oligomerisation and relay the death message to 
the mitochondria [132]. This commits a cell to apoptosis by inducing the formation of the outer 
mitochondrial membrane pore [132, 133]. While the molecular nature of the outer mitochondrial 
membrane pore is not fully understood, it functions as a non-specific protein channel that facilitates 
the egress of apoptotic effectors that reside within the inner mitochondrial space [132]. Cytochrome 
C is a hallmark apoptotic effector, harboured inside the inner mitochondrial space, which is released 
though the outer mitochondrial membrane pore [134, 135]. Cytosolic cytochome C is then available 
to form a caspase-activating scaffold, with apoptotic protease activating factor 1 (Apaf1) in a dATP-
dependant manner [136]. Caspase-9 is recruited and activated to this caspase-activating scaffold, 
which is known as an ‘apoptosome’ and subsequently activates downstream caspases such as caspase-
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3; which execute apoptosis by dismantling the cell [137]. An overall schematic of intrinsic apoptosis 
is shown in Figure 1-5. 
1.3.3.2 Extrinsic apoptosis  
Extrinsic apoptosis is a receptor mediated pathway of programmed cell death involving ligand 
activation of the death receptors, DR4 and DR5, expressed in the plasma membrane [138]. The 
tumour necrosis factor (TNF) superfamily are death receptor ligands, including the TNF-related 
apoptosis-inducing ligand (TRAIL). TRAIL binds to either death receptor, DR4 or DR5 on the 
extracellular face of the plasma membrane and induces death receptor trimerisation [139]. This 
facilitates clustering of their intracellular death domains and yields a death inducing signalling 
complex (DISC) [139]. Fas-associated death domain (FADD) is an adapter protein that binds to the 
DISC signalling complex and the resultant protein scaffold recruits and activates caspase-8 [139]. 
Active caspase-8 subsequently stimulates downstream caspases to execute apoptosis [140]. 
Alternatively, caspase-8 can recruit the intrinsic apoptotic pathway by cleaving Bid [141, 142]. 
Caspase-8 cleaves the BH3-only protein, Bid into its active fragment, tBid to unleash its pro-apoptotic 
properties [141, 142]. Redistribution of tBid to the mitochondrial membrane induces formation of the 
outer mitochondrial membrane pore in a Bax and Bak-dependant mechanism [143]. Figure 1-5 






Intrinsic and extrinsic apoptosis are the two key pathways that mediate programmed cell death [128]. 
(a) The intrinsic pathway is coordinated by the cell’s mitochondria [129]. For example, a death signal 
like staurosporine is sensed by the BH3-only proteins (yellow circle), which activate Bax and Bak 
(green circle) [144, 145]. Bax and Bak are proapoptotic, Bcl-2 proteins that relay this death message 
to the mitochondria by opening the outer mitochondrial membrane pore, which facilitates the release 
of cytochrome C (orange circle) from the mitochondria into the cell’s cytoplasm [129]. Cytosolic 
cytochrome C forms a caspase-activating scaffold with Apaf1 and dATP, known as an apoptosome 
[136]. Caspase-9 is activated upon this apoptosome and subsequently activates caspase-3, which 
executes apoptosis [137]. (b) The extrinsic pathway involves activation of death receptors (blue) at 
the plasma membrane by ligands including TRAIL [139]. Ligand-binding prompts receptor 
trimerisation through their death domains (pink) and recruitment of the adaptor protein, FADD [139]. 
The resulting caspase-activating scaffold recruits and activates caspase-8 [139]. The initiator caspase-
8 can activate caspase-3 to execute apoptosis [140]. Alternatively, caspase-8 cleaves the BH3-only 
protein, Bid into tBid (yellow circle) [141, 142]. tBid recruits the intrinsic apoptotic pathway by 
opening the outer mitochondrial membrane pore to evoke downstream events like cytochrome C 
release [143]. Ca2+ accumulation within the mitochondria, which is largely dependent on the local 
transfer of Ca2+ from the ER, can lead to the opening of the mitochondrial PTP on the inner 
mitochondrial membrane [146-148]. The Ca2+-induced mitochondria PTP is a potent stimulant for 
the opening of the outer mitochondrial membrane pore and consequently Ca2+ is a key modulator of 
programmed cell death [149-151]  
Figure 1-5: Apoptosis signalling pathways.  
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1.3.4 The apoptosis-calcium link 
An increase in intracellular Ca2+ accompanies many apoptotic insults including ceramide [152] and 
staurosporine [144, 145]. These death inputs activate intrinsic apoptosis [144, 145, 152], detailed in 
section 1.3.3.1, page 25 (Figure 1-5). Mechanistically, intrinsic apoptosis is coordinated by the cell’s 
mitochondria and involves cytochrome C release through the outer mitochondrial membrane pore. 
Mitochondrial Ca2+ signals can induce the formation of another pore, the permeability transition pore 
(PTP), located on the inner mitochondrial membrane, which results in the loss of ion gradients and 
dissipation of the mitochondrial membrane potential [153]. [Ca2+]MIT increases, can therefore trigger 
apoptosis by prompting the PTP, which can then trigger the opening of the outer mitochondrial 
membrane pore [144, 145, 154] and commit a cell to undergo apoptosis [132, 133].  
1.3.4.1 Calcium and the mitochondrial PTP 
The opening of the mitochondrial PTP is regulated by Ca2+ and influenced by the parameters of the 
Ca2+ signal experienced by mitochondria, including the amplitude, frequency [147] and duration 
[146, 148]. A subpopulation of mitochondria positioned in close proximity to the ER experience 
[Ca2+]MIT signals ranging from 5 µM up to concentrations of 500 µM [30, 35]. These are 
concentrations sufficient to induce the permeability transition pore [144, 145, 154]. As discussed in 
section 1.1.4.1 (page 8), the transfer of Ca2+ between the ER and mitochondria depends on IP3-
mediated Ca2+ store release [155, 156]. Therefore, the link between Ca2+ and apoptosis has been 
examined with agonists such as ATP, because these agents generate IP3-mediated Ca
2+ store release 
[144, 145, 151, 152]. Figure 1-5 shows Ca2+ accumulation in mitochondria, via the local transfer of 




1.3.4.2 Apoptosis and IP3-store release of calcium 
Elevations in [Ca2+]MIT can be decoded by the mitochondria to paradoxically, promote both cell 
survival and cell death [4]. Hajnoczky et al. evaluated IP3-mediated Ca
2+ store release during 
apoptosis in whole cells, exposed to ATP in the absence and presence of the death initiators 
staurosporine or ceramide [149-151]. Cells exposed to ATP alone experienced a small mitochondrial 
membrane depolarisation, which does not activate the apoptotic program, but instead elevates ATP 
synthesis to energise and support cell survival [149-151]. This finding is consistent with the previous 
literature, where [Ca2+]MIT in the range of 0.1 µM to 3 µM [157], is a positive regulator of 
dehydrogenases [158] and elevates ATP synthesis for cell survival [159]. In contrast, cells exposed 
to ATP and either staurosporine or ceramide experienced mitochondrial membrane depolarisation 
that released cytochrome C release and triggered apoptosis [149-151]. This has led to the hypothesis 
that the co-incident detection of Ca2+ and an apoptotic agent by the mitochondria is efficient to initiate 
apoptosis [149-151]. In this model, regulating [Ca2+]MIT would be expected to alter the sensitivity of 
cells to apoptosis initiated by a death stimulus, whose mechanism involves the mitochondria. 
1.3.4.3 Anti-apoptotic Bcl-2 proteins 
The founding member of the Bcl-2 protein family, Bcl-2 is localised to the ER and mitochondrial 
membrane and this observation provided the first clue that Ca2+ may modulate apoptosis [160]. 
Indeed, the anti-apoptotic effect of Bcl-2 works in part, by reducing the [Ca2+]ER and decreasing Ca
2+ 
uptake into the mitochondria when the IP3-senstitive Ca
2+ store is released [161, 162]. This protects 
cells from apoptosis by preventing activation of the mitochondrial PTP. Pinton et al. confirmed the 
significance of [Ca2+]ER during apoptosis by manipulating [Ca
2+]ER levels. HeLa cells exposed to 
thapsigarin or genetically manipulated to overexpress PMCA, mimicked the effects of Bcl-2 by 
reducing [Ca2+]ER [117, 163]. Under these conditions, where [Ca
2+]ER was reduced, HeLa cells were 
protected from ceramide-induced apoptosis [152]. Conversely, high [Ca2+]ER levels achieved by 




1.3.5 PMCAs and apoptosis 
Initial studies of PMCA-mediated regulation of apoptosis was explored by two independent 
laboratories using gain-of-function models, where PMCA4b was overexpressed in a panel of cell 
lines [73-76, 164]. These studies identified a caspase-3 consensus site in the primary sequence of 
PMCA4b, DEID, located upstream of the calmodulin binding domain (Figure 1-4) [75, 76]. 
Preventing caspase-3 mediated cleavage of PMCA4b significantly delayed apoptosis [75, 76]. 
However, the consequence of caspase-3 cleavage on PMCA4b pump activity and localisation have 
been conflicting [73-76]. Some studies indicate that caspase-mediated cleavage fully activates 
PMCA4 [73-75], and other studies suggest that caspase-mediated cleavage can inactivate this calcium 
pump isoform [76]. 
1.3.6 Summary 
Gain-of-function studies have been instrumental in demonstrating that PMCA upregulation can delay 
and protect cells from undergoing apoptosis. Aberrant PMCA overexpression identified in various 
cancers including those of the breast, could consequentially promote the cancer phenotype by 
enabling them to escape cell death. Some studies have examined the potential roles of PMCA 
isoforms in apoptosis in breast cancer cells, but as described below, at the time the experiments for 




1.4 Breast Cancer 
1.4.1 Introduction 
The most common cancer in female Australians is breast cancer. A recent publication – Breast cancer 
in Australia: an overview –  provides the latest information and national statistics on breast cancer in 
Australia [165]. Not only has the number of women diagnosed with this disease per year doubled 
since1982, but records show that in 2007 breast cancer (after lung cancer) was the second most 
common cause of cancer-related deaths in females [165]. Despite improved diagnosis and availability 
of breast cancer management regimes, the incidence of breast cancer is steadily increasing. Future 
projections indicate that there will be 14,610 new cases in 2012, compared with 17,210 new cases in 
2020 [165]. Moreover, the burden of breast cancer in Australia exceeds that of all other female 
cancers, and is associated with significant premature mortality [165]. These statistics highlight that 
continued research is essential to improve breast cancer management.   
1.4.2 Molecular classification of breast cancers 
In 2000, Peru et al. proposed that heterogeneous diversity amongst breast tumours is accompanied 
by differential gene expression patterns that could be captured from their gene expression profile 
[166]. This original study used cDNA microarray profiling of forty human breast tumours, grouped 
on the basis of similarities and differences in their gene expression [166]. Of the five breast cancer 
subtypes defined, the most striking difference was detected between the luminal-like and basal-like 
subtypes [166, 167]. Luminal-like tumours are the largest cluster and express the oestrogen receptor, 
along with many other genes expressed by non-malignant luminal breast cells [166, 167]. Whereas, 
basal-like tumours are oestrogen receptor negative and express many genes characteristic of non-
malignant basal breast epithelial cells [166, 167]. The Erb-B2 tumour subtype is also oestrogen 
receptor negative, but overexpresses the Erb-B2 oncogene [166, 167].  
Such molecular diversity amongst human breast cancers, validated by subsequent studies [168, 169], 
is significant because it correlates with marked differences in their prognosis and response to 
chemotherapy [167, 170]. In order to improve the outcome for women diagnosed breast cancer, new 
tumour suppressing drugs that target the pathways deregulated in these breast cancer subtypes are 
needed. This approach is particularly urgent for the more aggressive basal-like breast cancers, which 
owing to their usual lack of HER2, oestrogen receptor and progesterone receptor expression respond 
poorly to the available therapies including tamoxifen (ER antagonist) and Herceptin (HER2 
antagonist) [167, 170].  
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1.4.3 Calcium and cancer 
Proliferation, angiogenesis, replicative immortality, evasion to growth suppressors, resistance to cell 
death and metastasis are all features of cancer cells [119, 171]. Ca2+ transporters, because they 
regulate many of these pathways deregulated in cancer, are anticipated targets for future anti-cancer 
drug development [21].  
The significance of the Ca2+ permeable ion channel TrpM8 and its upregulation reported in prostate 
cancer has been assessed [172]. In the human LNCap prostate cancer cell line, siRNA-mediated 
silencing of TrpM8 attenuates cell proliferation, whereas the TrpM8 agonist menthol triggers 
apoptosis [173]. Altered expression of another Ca2+ permeable ion channel, Orai1 is documented in 
breast cancer cell lines compared with the non-tumourgenic controls [174]. Orai1 plays a key role in 
store operated Ca2+ entry, activated by the depletion of Ca2+ within the endoplasmic reticulum. The 
consequence of Orai1 silencing has been examined in MDA-MB-231 breast cancer cells, and 
attenuates cell migration and invasion [175]. These studies of TrpM8 and Orai1 support the view that 
Ca2+  transport proteins are plausible anti-cancer drug targets [21] 
1.4.4 Breast cancer and PMCAs 
Another calcium transporter potentially important in terms of cancer is the calcium pump PMCA. 
Reports of either PMCA up or downregulation in various cancers [176-180] indicates that remodeling 
of PMCA-mediated Ca2+ efflux may regulate cancer-relevant pathways such as proliferation and/or 
the resistance to apoptosis.  Altered PMCA expression was initially reported in SV40-transformed 
skin and lung fibroblasts [181].  PMCA1 and PMCA4 were significantly downregulated in SV40-
transformed cells compared with the non-transformed cells [181]. The relevance of PMCA4 
downregulation, which is also a feature of colon cancers, has been examined by silencing or 
overexpressing this PMCA isoform in the HT-29 colon cancer cell line [180]. PMCA4 
downregulation augments HT-29 cell proliferation and provides a growth advantage, without exerting 
effects on cell viability [180].    
PMCA expression has also been examined in breast cancers. However, unlike colon cancer where 
PMCA4 downregulation is detected, PMCA upregulation is typical of some breast cancer cell lines 
[178, 179] that are different in their oestrogen and HER2 receptor status [178, 179]. In some of these 
breast cancer cell lines, PMCA2 is markedly upregulated from undetectable levels up to 100-fold; 
whereas PMCA1 is only modestly upregulated, and PMCA4 modestly downregulated [178, 179]. 
PMCA expression in breast cancer, is to some degree, similar to the changes observed in the lactating 
mammary gland. Significant PMCA2 upregulation in lactating mammary epithelial cells, increases 
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their Ca2+ efflux capacity, and this is critical for Ca2+ secretion into milk, along with the promotion 
of cell survival and maintenance of low intracellular Ca2+ levels [58, 59, 107, 108]. In the pathological 
setting, aberrant PMCA2 upregulation in breast cancer cells is predicted to reduce intracellular Ca2+ 
levels, and may promote cancer-relevant pathways such as resistance to cell death and/or disrupt cell 
cycle progression. Indeed, recombinant PMCA2 expression protects against T47D breast cancer cell 
death following treatment with either docetaxel or ionomycin [182]. Since PMCA2 upregulation in 
breast cancer cells protects against cell death; PMCA2 inhibition, via elevations of intracellular Ca2+ 
is proposed to promote breast cancer cell death. Very recent PMCA2 studies report that the silencing 
of this PMCA isoform attenuates MDA-MB-231 breast cancer cell proliferation [183], and promotes 
SKBr3 breast cancer cell death initiated with the Ca2+ ionophore ionomycin [182, 184]. However, the 
consequence of isoform specific PMCA knockdown on cell death in a basal-like breast cancer cell 
line has not reported, and the consequence of silencing of specific PMCA isoforms in the promotion 
of cell death initiated through different mechanisms is still not well understood.  
1.4.5 Summary 
PMCA-mediated regulation of breast cancer cell death has been reported, but the majority of these 
studies have involved PMCA overexpression. To assess whether specific PMCA isoforms may serve 
as therapeutic targets for future breast cancer therapy, PMCA inhibition and/or silencing studies are 
required.  Pharmacological assessment of PMCA isoforms is restricted by the lack of available 
isoform-specific inhibitors. Some studies have examined the consequences of PMCA silencing in 
breast cancer. These studies, however have only examined PMCA2 and did not assess isoform-
specific PMCA silencing in a basal-like breast cancer cell line that overlaps with triple negative breast 
cancers, which are generally more aggressive than other breast cancer subtypes. In this thesis, the 
consequence of isoform-specific PMCA silencing in the basal-like MDA-MB-231 breast cancer cell 






1.5 Hypotheses and Aims 
Work undertaken in this thesis was designed to delineate the role of specific PMCA isoforms in the 
regulation of cytoplasmic Ca2+ signals and on different mechanisms of cell death in the MDA-MB-
231 breast cancer cell line. Experiments were performed in the MDA-MB-231 breast cancer cell line 
because these cells express many of the genes characteristic of aggressive, basal-like breast cancer 
subtypes that urgently require new therapeutic options.  This cell line was also selected because 
MDA-MB-231 cells, along with the PMCA isoforms PMCA1, PMCA4 and PMCA2, express the 
protease caspase-3 that is essential for the execution of many apoptotic pathways [137]. 
This thesis research is divided into three chapters. Chapter 2 discusses the development of a high-
throughput cell death assay, and details the impact of silencing PMCA1 or PMCA4 on [Ca2+]CYT 
signals and on cell death mechanisms. Chapter 3 extends these studies to PMCA2. Chapter 4 
examines the potential for PMCA-silencing to exert effects on cell death via mitochondrial calcium 
levels indirectly by evaluating MCU silencing-mediated effects on [Ca2+]CYT and on cell death 
mechanisms. Chapter-specific aims and hypothesis are listed at the beginning of each chapter. Listed 
below are the overall hypotheses relevant to this thesis as a whole.  
1.5.1 Hypothesis 1 
Silencing of specific PMCA isoforms differentially regulates the sensitivity of MDA-MB-231 breast 
cancer cells to agents that initiate cell death via different mechanisms 
1.5.2 Hypothesis 2 
Silencing of specific PMCA isoforms distinctly regulate global cytoplasmic Ca2+ signals in MDA-
MB-231 breast cancer cells and this relates to their effects on cell death 
1.5.3 Hypothesis 3  





Chapter 2 Assessment of Plasma Membrane Calcium Isoform 1 and 4 Silencing in the MDA-MB-231 
Breast Cancer Cell Line 
2.1 Preface 
Plasma membrane calcium (Ca2+) ATPase (PMCA) isoforms, although important for healthy 
mammary gland development, may also play a role in mammary gland pathophysiology.  PMCA-
mediated Ca2+ efflux, by way of reducing intracellular Ca2+ levels, may promote cancer hallmarks 
including proliferation and the resistance to cell death. Supporting this view, initial reports 
demonstrated that PMCA isoform expression is altered in breast cancer cell lines compared with non-
tumorigenic breast cancer cell lines [178] and antisense-mediated inhibition of PMCA expression 
attenuates MCF-7 breast cancer cell proliferation [185]. These studies established a link between 
PMCA and cancer, however, the differential impact of individual PMCA isoforms on cancer-relevant 
pathways in breast cancer is not clear and very few functional studies have been performed in basal-
like breast cancer cell lines.   
To evaluate whether individual PMCA isoforms can distinctly influence aspects of cancer biology, 
this chapter compared the functional effects of silencing either PMCA1 (siPMCA1) or PMCA4 
(siPMCA4) expression on cytoplasmic calcium signals ([Ca2+]CYT), cell viability and transcription 
factor activity in MDA-MB-231 breast cancer cells.  PMCA1 and PMCA4 were selected for these 
experiments because of their potential functional differences in the same cell, despite a significant 





This research was originally published in the Journal of Biological Chemistry. Curry MC, Luk NA, 
Kenny PA, Roberts-Thomson SJ, Monteith GR. Distinct regulation of cytoplasmic calcium signals 
and cell death pathways by different plasma membrane calcium ATPase isoforms in MDA-MB-231 
breast cancer cells. This publication is incorporated into this thesis chapter, with the original format 
of the manuscript adjusted to comply with the University of Queensland thesis formatting guidelines. 
The manuscript presents novel research findings that were predominantly designed and performed by 
myself under the supervision of Gregory R Monteith and Sarah J Roberts-Thomson. Additional data, 
performed by Nicole A Luk and Dr. Paraic A Kenny, was included in the manuscript and has been 
incorporated into this thesis chapter. During her PhD, Nicole A Luk performed the NFκB 
translocation studies shown in Figure 2-8A and B. Dr. Paraic A Kenny, an international collaborator, 





2.2 Chapter Hypotheses 
 Global [Ca2+] are distinctly altered by isoform-specific PMCA1 or PMCA4 knockdown. 
 ABT-263 and ionomycin trigger cell death pathways that are differentially dependent on 
caspase activity.  
 Isoform-specific PMCA1 or PMCA4 knockdown distinctly modulate cell death, in the 
absence and presence of cell death activators. 
 Isoform-specific PMCA1 or PMCA4 knockdown distinctly regulates nuclear translocation of 
nuclear factor κB (NFκB), which may represent a novel mechanism where by some PMCA 
isoforms regulate cell death. 
2.3 Chapter Aims 
 To reduce PMCA1 or PMCA4 expression using targeted siRNAs in the MDA-MB-231 breast 
cancer cells.  
 To monitor [Ca2+]CYT increases generated with CPA, ionomycin, ATP and trypsin in siRNA-
transfected (PMCA1 siRNA (siPMCA1) or PMCA4 siRNA (siPMCA4) or NT siRNA (siNT)) 
MDA-MB-231 cells by high-throughput imaging of relative [Ca2+]CYT using a fluorescence 
imaging plate reader (FLIPRTETRA). 
 To use the high content imaging assay developed to assess the consequence of PMCA1 and 
PMCA4 knockdown on MDA-MB-231 cell death in the absence and presence of the cell death 
activators, ABT-263, ionomycin, ceramide and staurosporine. 
 To determine effects of PMCA1 or PMCA4 knockdown on the nuclear translocation of 
nuclear factor kappa B (NFκB). 
 To ascertain the consequences of pharmacological inhibition of NFκB on caspase-dependent 





 Background: The roles of different PMCA isoforms are not fully understood particularly in 
cell death. 
 Results: PMCA4 and PMCA1 silencing has differential effects on Ca2+ signalling and caspase 
dependent and independent cell death in MDAMB-231 cells. 
 Conclusion: PMCA isoforms have distinct roles in the control of cell death pathways. 
 Significance: Inhibition of PMCA4 may increase the effectiveness of some cancer therapies. 
2.5 Summary 
PMCAs actively extrude Ca2+ from the cell and are essential components in maintaining intracellular 
Ca2+ homeostasis. There are four PMCA isoforms (PMCA 1-4) and alternative splicing of the PMCA 
genes creates a suite of calcium efflux pumps. The role of these different PMCA isoforms in the 
control of calcium-regulated cell death pathways and the significance of the expression of multiple 
isoforms of PMCA in the same cell type are not well understood. In these studies, we assessed the 
impact of PMCA1 and PMCA4 silencing on cytoplasmic free Ca2+ signals and cell viability in MDA-
MB-231 breast cancer cells. The PMCA1 isoform was the predominant regulator of global Ca2+ 
signals in MDA-MB-231 cells. PMCA4 played only a minor role in the regulation of bulk cytosolic 
Ca2+, which was more evident at higher Ca2+ loads. Although PMCA1 or PMCA4 knockdown alone 
had no effect on MDA-MB-231 cell viability, silencing of these isoforms had distinct consequences 
on caspase-independent (ionomycin) and dependent (ABT-263) cell death. PMCA1 knockdown 
augmented necrosis mediated by the Ca2+ ionophore ionomycin, whereas apoptosis mediated by the 
Bcl-2 inhibitor ABT-263 was enhanced by PMCA4 silencing. 
PMCA4 silencing was also associated with an inhibition of NFκB nuclear translocation and an NFκB 
inhibitor phenocopied the effects of PMCA4 silencing in promoting ABT-263 induced cell death. 
This study demonstrates distinct roles for PMCA1 and PMCA4 in the regulation of calcium signalling 
and cell death pathways despite the widespread distribution of these two isoforms. The targeting of 
some PMCA isoforms may enhance the effectiveness of therapies that act through the promotion of 





Studies have started to identify some of the potential mechanisms that may underpin the functions 
predicted for specific PMCA isoforms. One such example is the differential association of PMCA1, 
PMCA2 and PMCA4 with calcineurin in MCF-7 cells [186]. The functional significance of this 
interaction has not been investigated in MCF-7 cells, however, in cardiac cells PMCA4 regulates 
nuclear factor of activated T-cells (NFAT), a calcineurin regulated transcription factor, and cardiac 
hypertrophy [187]. 
One process where the relative contribution of specific PMCA isoforms may be particularly 
important, but has not been fully addressed is cell death, where the duration and amplitude of 
increases in [Ca2+]CYT are critical [4, 188]. Initiators of cell death include Ca
2+ ionophores that 
produce sustained (µM) increases in [Ca2+]CYT that can induce necrotic cell death [6] and inhibitors 
of B cell lymphoma-2 protein (Bcl-2) [189-191]. Bcl-2 inhibitors promote apoptosis by blocking the 
prosurvival activity of Bcl-2 proteins [189-191] and are undergoing clinical trial assessment for the 
treatment of specific types of lymphomas and solid lung cancers [192].  
A few studies have assessed the consequences of PMCA expression on cell death. In HeLa cells, 
PMCA overexpression protects from ceramide induced cell death [152]. The authors attributed this 
to alterations in intracellular Ca2+ stores, given that PMCA overexpression in CHO cells reduces Ca2+ 
levels within the endoplasmic reticulum and mitochondria [163]. In the context of breast cancer, 
where cells acquire the ability to evade cell death [171], assessment of PMCA has been restricted to 
overexpression studies in T47D breast cancer cells [182]. Recombinant PMCA2 expression 
attenuates increases in [Ca2+]CYT, associated with ionomycin induced cell death [182].  
Although PMCA2 knockdown has been assessed in spinal cord neurons [193] and SH-SY5Y 
neuroblastoma cells [194], and PMCA4 knockdown evaluated in HT-29 colon cancer cells [180], 
isoform-specific PMCA knockdown has not yet been studied in breast cancer cells. In addition, the 
differential role of PMCA isoforms in the regulation of distinct cell death mechanisms, within the 
same cell type has not been evaluated. In the present study we compared siRNA-mediated knockdown 
effects of PMCA1 and PMCA4 in the regulation of global Ca2+ signals and assessed the effects on 
the viability of MDA-MB-231 breast cancer cells, in the absence and presence of the cell death 
initiators, ionomycin (Ca2+ ionophore) and ABT-263 (Bcl-2 inhibitor). The basal breast cancer 
molecular subtype is associated with a particularly poor prognosis, therefore MDA-MB-231 breast 




2.7 Experimental Procedures 
2.7.1 Cell culture 
The human breast cancer cell line MDA-MB-231 (American Type Culture Collection) was cultured 
in high glucose DMEM (Sigma Aldrich) supplemented with 10% FBS and 4 mM L-glutamine 
(Gibco) at 37°C/5% CO2 in a humidified air incubator. All cultures were periodically screened for 
mycoplasma infection. 
2.7.2 siRNA-mediated knockdown of PMCA4 and PMCA1 gene expression 
MDA-MB-231 cells were seeded into 96-well plates and allowed to adhere overnight. DharmaFECT 
4 (0.1-0.2 µL/well, Dharmacon) was used to transfect cells with Dharmacon ON-TARGETplus™ 
SMARTpool siRNA, which consists of four pooled siRNA sequences rationally designed to minimise 
off target effects [195, 196]. Transfection media was prepared according to the manufacturer’s 
protocol and contained 8% FBS. The siRNAs used in this study included those for PMCA4 
(siPMCA4, L-006118-00), PMCA1 (siPMCA1, L-006115-00) and the non-targeting control siRNA 
(siNT, D-001810-10). All experiments had mRNA knockdown >70% at 24 h or 48 h post-siRNA 
2.7.3 Real time RT-PCR 
Cells were plated at 5.0×103 cells per well into 96-well plates and siRNA-transfected. Total RNA 
was isolated (RNeasy Plus Mini Kit; Qiagen) 24 h, 48 h or 120 h post-transfection and then reverse 
transcribed using the Omniscript RT kit (Qiagen) according to the manufacturer’s protocol. Target 
cDNA were amplified using the TaqMan Fast Universal PCR Master Mix (Applied Biosystems) and 
TaqMan Gene Expression assays (PMCA4, Hs00608066_m1; PMCA1, Hs00155949_m1) and 
standard cycling conditions with a StepOnePlus Real Time PCR system (Applied Biosystems). 
PMCA4 and PMCA1 mRNA levels were quantified by the comparative Ct method as previously 




2.7.4 Cytoplasmic free calcium measurements 
MDA-MB-231 cells were plated at 7.5×103 cells per well into 96-well plates and siRNA transfected. 
Transfection media was removed 72 h post-siRNA treatment and cells were loaded with culture 
medium containing Fluo-4 AM (4 µM; Molecular Probes) or Fluo-4FF AM (4 µM; Molecular Probes) 
and incubated at 37°C for 30 min in a 5% CO2 humidified air incubator. Loading solution was 
replaced with physiological salt solution (PSS; 5.9 mM KCl, 1.4 mM MgCl2, 10 mM HEPES, 1.2 
mM NaH2PO4, 5 mM NaHCO3, 140 mM NaCl, 11.5 mM Glucose, 1.8 mM CaCl2), cells were 
equilibrated to room temperature and then washed twice with PSS containing bovine serum albumin 
(BSA, 0.3%). [Ca2+]CYT was measured in Ca
2+ probe loaded cells using a fluorescence imaging plate 
reader [198] (FLIPRTETRA, Molecular Devices Corporation) using an excitation intensity of 470-495 
nm and a 515-575 nm emission filter. Fluorescence was normalised to baseline values to assess 
relative [Ca2+]CYT. 
2.7.5 Immunoblotting 
Cells were plated at 5.0×103 cells per well into 96-well plates and siRNA transfected. Cell extracts 
were harvested 72 h post transfection in protein lysis buffer supplemented with protease inhibitor 
cocktail (Roche Applied Science) as previously described [180]. Proteins were separated using gel 
electrophoresis and transferred onto a polyvinylidene fluoride membrane as previously described 
[199]. 
Membranes were probed with monoclonal antiPMCA4 antibody (1:1000, JA9, Pierce Antibodies), 
monoclonal anti-PMCA antibody (1:2000, 5F10, Pierce Antibodies) and monoclonal anti-β-actin 
antibody (1:10,000, Sigma Aldrich). Anti-mouse horseradish peroxidase-conjugated secondary 
antibody (1:10000, BioRad) was used to visualise protein bands by chemiluminescence using Super-
Signal West Dura (Pierce). All antibodies were diluted in PBST (0.1% Tween-20 in PBS) with skim 
milk powder (2.5%). Images were acquired and analysed by densitometry using a VersaDoc 
instrument and Quantity One Analysis software (Bio-Rad), respectively. All data were normalised to 
the β-actin loading control and are presented relative to siNT. 
2.7.6 Assessment of cell viability 
MDA-MB-231 cells were plated at 5.0×103 cells per well into 96-well plates and siRNA-transfected. 
At 72 h post-transfection media was removed and cells were treated with ABT-263 (Selleckchem), 
ionomycin (Enzo Life Sciences), Z-VAD-FMK (Enzo Life Sciences), IMD-0354 (Sigma-Aldrich) or 
DMSO (up to 1%) for 48 h in phenol-red free DMEM containing FBS (8%). Live cells were stained 
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at 37°C for 15 min with Hoechst 33342 (10 µg/mL, Invitrogen) and propidium iodide (1 µg/mL, 
Invitrogen). Images were acquired using an ImageXpress micro automated epifluorescence 
microscope (Molecular Devices Corporation) with a 10X objective, a system previously used for cell 
death assays [200-202]. Four images were automatically acquired per well in the DAPI and Cy3 
channel for Hoechst 33342 and propidium iodide respectively. The multi-wavelength cell scoring 
application module (MetaXpress v3.1.0.83; Molecular Devices Corporation) was used to segment 
cell nuclei to calculate the average Hoechst 33342 integrated intensity and the average propidium 
iodide intensity emitted per cell. Criteria for viable, apoptotic and necrotic (and secondary apoptosis) 
are shown graphically in figures and validated using the caspase inhibitor Z-VAD-FMK. 
2.7.7 Assessment of NFκB nuclear translocation 
MDA-MB-231 cells were plated at 3.5×103 cells per well into 96-well plates and transfected with 
siRNA. Post-siRNA transfection (48 h), media was removed and cells were serum reduced (2% FBS) 
for 12 h, prior to the addition of phorbol 12- myristate 13-acetate (PMA, 50 nM, Sigma) or DMSO 
(0.05%) for 1 h in DMEM (10% FBS) [203]. Cells were fixed (4% paraformaldehyde in PBS), 
blocked (PBS, 5% normal goat serum and 0.3% Triton X-100) and then stained with the polyclonal 
anti-NFκB p65 antibody (Cell Signaling Technologies) diluted 1:100 in PBS containing BSA (1%) 
and Triton X-100 (0.3%). NFkB was visualised using anti-rabbit IgG (H+L), F(ab')2 Fragment Alexa 
Fluor® 555 Conjugate Secondary antibody (1:500, Cell Signaling Technologies). Cell nuclei were 
stained with DAPI (40 nM, Invitrogen) and images acquired using an ImageXpress micro automated 
epifluorescence microscope (Molecular Devices Corporation) with a 10X objective as described 
above. The ImageXpress platform has been utilised in translocation studies previously [204] and the 
basis of the translocation assay has been reviewed [205]. NFκB translocation was assessed using the 




2.7.8 Analysis of PMCA1 and PMCA4 levels in published datasets 
Gene expression data for breast cancer cell lines in 3D culture [206] or for breast tumors [207] were 
obtained from online repositories (ArrayExpress no. E-TABM-244 (cell lines) and NCBI GEO no. 
GSE2034 (tumors)). Affymetrix probes for PMCA1 (215716_s_at) and PMCA4 (212136_at) were 
shared between these datasets. Samples were stratified based on their reported annotations (basal 
versus luminal for cell lines, and ER- versus ER+ for tumors). Normalised gene expression levels 
(log2) were plotted and median levels of each gene were compared between groups (Mann-Whitney 
test). For relapse free survival analysis, tumors were stratified into groups corresponding to the upper 
and lower quartiles and the interquartile range for Kaplan-Meier analysis.  
2.7.9 Statistical Analysis 
All statistical tests were performed as described in the figure legends using GraphPad Prism (version 
5.04) for Windows. For cell death, given the batch to batch variability of ionomycin, for all studies 






2.8.1 siRNA-mediated knockdown of specific PMCA isoforms in MDA-MB-231 breast cancer cells  
There was a significant (P < 0.05) reduction in PMCA4 (Figure 2-1A) and PMCA1 (Figure 2-1B) 
mRNA levels in cells transfected with PMCA4 siRNA or PMCA1 siRNA, respectively, compared to 
the siNT control. PMCA4 protein expression was also significantly (P < 0.05) reduced by PMCA4 
siRNA (Figure 2-1C and D), but was not associated with significant changes in total PMCA protein 
expression (Figure 2-1C and E). Consistent with high levels of PMCA1, total PMCA protein levels 
were reduced by PMCA1 siRNA (Figure 2-1C and E; P < 0.05). This was not associated with changes 
in PMCA4 expression (Figure 2-1C and D).
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Figure 2-1: Silencing of PMCA4 and PMCA1 in MDA-MB-231 cells.  
Quantification of (A) PMCA4 mRNA and (B) PMCA1 mRNA levels, 48 h post-siRNA transfection with 
siPMCA4, siPMCA1 or siNT. Real time RT-PCR data were pooled from three independent experiments 
performed in triplicate, *P < 0.05, one-tailed student’s t test. (C) Immunoblots of PMCA4 and total 
PMCA protein expression, 72 h post-siRNA transfection. (D) PMCA4 and (E) total PMCA protein 
expression from densitometic analysis normalised to the β-actin loading control, from three independent 





2.8.2 Consequences of PMCA1 or PMCA4 knockdown on cytoplasmic free calcium in MDA-MB-231 
breast cancer cells 
In the absence of extracellular Ca2+, increases in [Ca2+]CYT elicited by the sarcoplasmic-endoplasmic 
reticulum Ca2+-ATPase inhibitor cyclopiazonic acid (CPA, 10 µM) were markedly altered with 
siRNA-mediated knockdown of PMCA1, but not by PMCA4 knockdown (Figure 2-2A-D). PMCA1 
silencing significantly (P < 0.05) delayed the time to reach the maximal Ca2+ response (Figure 2-2B), 
increased the half-peak decay time (Figure 2-2C) and increased the area under the curve (Figure 
2-2D) compared to siNT. The effect was isoform-specific, as PMCA4 knockdown did not alter the 
nature of the CPA-induced Ca2+ response when compared with siNT (Figure 2-2A-D).  
The purinergic receptor agonist ATP (100 µM) induced a rapid rise in [Ca2+]CYT (Figure 2-2E), with 
no significant difference in the peak maximum between siRNA treatments (mean ± SD; siPMCA1, 
2.56 ± 0.23; siPMCA4, 2.68 ± 0.31; siNT, 2.99 ± 0.39). However, PMCA1 knockdown significantly 
altered the recovery of [Ca2+]CYT after ATP stimulation (Figure 2-2F-H) in comparison to siNT, 
resulting in a slower rate of [Ca2+]CYT decay in the absence of extracellular Ca
2+ (Figure 2-2F), a delay 
in half peak decay time (Figure 2-2G) and an increase in the area under the curve (Figure 2-2H). 
These effects were isoform-specific as similar changes were not seen with PMCA4 silencing (Figure 
2-2E-H). To assess the consequences of isoform-specific PMCA knockdown with [Ca2+]CYT increases 
of a greater magnitude, we compared the effects of PMCA4 or PMCA1 siRNA on [Ca2+]CYT changes 
mediated by the Ca2+ ionophore ionomycin in the presence of extracellular Ca2+ (1.8 mM).  
Increases in [Ca2+]CYT mediated by ionomycin (3 µM) were significantly (P < 0.05) increased with 
PMCA1 or PMCA4 knockdown compared to siNT (Figure 2-3A and B). These effects were more 
pronounced (P < 0.05) with PMCA1 knockdown compared to PMCA4 knockdown (Figure 2-3A and 
B). Silencing of PMCA1 or PMCA4 also augmented increases in [Ca2+]CYT mediated by 10 µM 
ionomycin, however, in contrast to 3 µM ionomycin there were no differences in effect between the 




Figure 2-2: Effect of PMCA1 and PMCA4 silencing on CPA and ATP evoked [Ca2+]CYT increases in 
MDA-MB-231 breast cancer cells.  
(A) CPA (10 µM)-mediated and (E) ATP (100 µM)-mediated [Ca2+]CYT after transfection with 
siPMCA1, siPMCA4 or siNT in the presence of extracellular BAPTA (100 µM). Ca2+ traces represent 
relative mean fluorescence. (B and F) Time to peak [Ca2+]CYT and rate of [Ca
2+]CYT decay after CPA and 
ATP responses, respectively. (C and G) Half peak decay time for CPA and ATP responses, respectively. 
(D and H) Area under the curve for CPA and ATP responses, respectively. Bar graphs are mean ± SD 
for Ca2+ transient parameters. All data were pooled from nine individual wells, from three independent 
experiments performed in triplicate. *P < 0.05, one-way ANOVA, Bonferroni post-hoc analysis. 








Figure 2-3: Ionomycin-evoked [Ca2+]CYT signals in the presence of PMCA1 and PMCA4 silencing.  
MDA-MB-231 breast cancer cells were transfected with siPMCA1, siPMCA4 or siNT and changes in 
[Ca2+]CYT were assessed after the addition of ionomycin ((A) 3 µM or (C) 10 µM. Ca
2+ traces represent 
relative mean fluorescence. (B and D) Rate of [Ca2+]CYT increase for 3 µM and 10 µM ionomycin Ca
2+ 
responses, respectively. Bar graphs are mean ± S.D for Ca2+ transient parameters. All data were pooled 
from nine individual wells, from three independent experiments performed in triplicate. *P < 0.05, one-
way ANOVA, Bonferroni post-hoc analysis. 
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2.8.3 Assessment of PMCA1 or PMCA4 knockdown on cell viability in MDA-MB-231 breast cancer cells 
No effect on cell viability was detected with knockdown of PMCA4 (Figure 2-4A, B and D) or 
PMCA1 (Figure 2-4A, C and D) compared to siNT. PMCA1 and PMCA4 were effectively silenced 
at the time of the assessment of cell viability (Figure 2-4E and F). Reduced Ca2+-efflux mediated by 
either PMCA1 or PMCA4 silencing was therefore insufficient for the activation of cell death 





Figure 2-4: Cell viability in the presence of siRNA-mediated silencing of PMCA1 and PMCA4 gene 
expression.  
MDA-MB-231 breast cancer cells were transfected with siPMCA4, siPMCA1 or siNT, incubated for 
a further 48 h and then assessed for cell viability. Cell viability for (A) siNT, (B) siPMCA4 and (C) 
siPMCA1 presented as dot plots of Hoechst 33342 and propidium iodide fluorescence. Each dot plot 
shows an equal cell number (10,000 cells) randomly selected from three independent experiments 
performed in triplicate wells. (D) Bar graph showing the mean ± SD of the proportion of viable cells 
120 h post-siRNA transfection from 3 independent experiments performed in triplicate wells, *P < 
0.05, one-way ANOVA, Bonferroni post-hoc analysis. (E) PMCA4 mRNA and (F) PMCA1 mRNA 
levels, 120 h post-siRNA transfection with siPMCA4, siPMCA1, or siNT. Real time RT-PCR data 
were pooled from six individual wells, from three independent experiments performed in duplicate. 
* P < 0.05, one-tailed Student’s t test. 
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2.8.4 Mechanism of ionomycin and ABT-263 activated cell death in MDA-MB-231 cells 
To assess whether reduced PMCA1 or PMCA4 expression could alter the responsiveness of breast 
cancer cells to different cell death mechanisms, we first characterised cell death in MDA-MB-231 
cells initiated by the Ca2+ ionophore ionomycin (Figure 2-5A and C) and the Bcl-2 inhibitor, ABT-
263 (Figure 2-5A and E). Ionomycin (10 µM) and ABT-263 (10 µM) both initiated significant (P < 
0.05) increases in cell death compared to control (Figure 2-5G and H). The nature of the initiated cell 
death was probed using the pan-caspase inhibitor, Z-VAD-FMK (50 µM). Consistent with a necrotic 
mechanism (13) ionomycin (10 µM)-induced cell death was not affected by Z-VAD-FMK (Figure 
2-5C, D and G) whereas cell death initiated by ABT-263 was almost entirely prevented by caspase 




Figure 2-5: Effects of the caspase inhibitor Z-VAD-FMK on ionomycin and ABT-263 mediated cell 
death in MDA-MB-231 breast cancer cells.  
(A-F) Dot plots for control, ionomycin or ABT-263 in either in the absence or presence of Z-VAD-FMK. 
Each dot plot represents an equal number of total cells (10,000 cells) selected at random from three 
independent experiments. (G and H) The pooled data for the effect of Z-VAD-FMK on the proportion 
of dead cells induced by ionomycin or ABT-263 (mean ± S.D), from three independent experiments. *P 




2.8.5 Consequences of PMCA1 or PMCA4 silencing on ionomycin-induced necrosis in MDA-MB-231 
breast cancer cells 
Necrosis mediated by submaximal ionomycin (3 µM) was not significantly affected by PMCA4 
knockdown (Figure 2-6A, B and G), however, it was significantly (P < 0.05) augmented with PMCA1 
silencing (Figure 2-6A, C and G).  
For the higher ionomycin concentration (10 µM) knockdown of both PMCA4 (Figure 2-6D, E and 
G) and PMCA1 (Figure 2-6D, F and G) significantly (P < 0.05) elevated the proportion of necrotic 
cells compared to siNT. However, similar to their effects on [Ca2+]CYT, the isoform-specific 
differences seen with submaximal ionomycin concentration (3 µM) were not detected at higher Ca2+ 




Figure 2-6: PMCA1 and PMCA4 silencing effects in promoting ionomycin-mediated cell death in 
MDAMB-231 breast cancer cells.  
Dot plots of Hoechst 33342 and propidium iodide fluorescence in cells transfected with (A and D) siNT, 
(B and E) siPMCA4, or (C and F) siPMCA1 following treatment with 3 µM or 10 µM ionomycin (iono). 
Each dot plot represents an equal number of total cells (10,000 cells) selected at random from three 
independent experiments. (G) The proportion of necrotic cells pooled from three independent 






2.8.6 Consequences of PMCA1 or PMCA4 silencing on ABT-263-induced apoptosis in MDA-MB-231 
breast cancer cells 
Submaximal ABT-263 (3 µM) induced-apoptosis was significantly (P < 0.05) augmented by PMCA4 
siRNA compared to siNT (Figure 2-7A, B and G). This effect was isoform-specific, as PMCA1 
knockdown did not alter apoptosis compared to siNT (Figure 2-7A, C and G). In contrast, ABT-263 
(10 µM)-mediated cell death was not modulated by either PMCA4 siRNA or PMCA1 siRNA 






Figure 2-7: PMCA1 and PMCA4 silencing effects in promoting ABT-263-mediated cell death in MDAMB-
231 breast cancer cells.  
Dot plots of Hoechst 33342 and propidium iodide florescence in cells transfected with (A and D) siNT, (B 
and E) siPMCA4, or (C and F) siPMCA1 following treatment with ABT-263 (ABT). Each dot plot 
represents an equal number of total cells (10,000 cells) selected at random from three independent 
experiments. (G) The proportion of apoptotic cells pooled from three independent experiments (mean ± S.D). 




2.8.7 PMCA4 but not PMCA1 knockdown inhibits NFκB translocation in MDA-MB-231 breast cancer 
cells 
Nuclear factor-κB (NFκB) is a Ca2+ dependent transcription factor [209-211], which is implicated in 
breast cancer progression [212] and the resistance to cancer therapies [213, 214]. PMCA4 is linked 
to the regulation of Ca2+ dependent transcription factors such as NFAT, independent of bulk [Ca2+]CYT 
changes [187]. We assessed the effects of PMCA4 and PMCA1 silencing on nuclear translocation of 
NFκB induced by PMA (50 nM) [203]. PMA-induced NFκB nuclear translocation (Figure 2-8A and 
B) was not affected by PMCA1 silencing but was significantly (P < 0.05) reduced by PMCA4 siRNA 
relative to siNT.  
2.8.8 Effects of NFκB inhibition on ABT-263- induced MDA-MB-231 cell death 
To further explore the possible link between PMCA4 and NFκB on MDA-MB-231 cell death, we 
assessed whether NFκB inhibition could mimic PMCA4 siRNA by augmenting cell death induced 
by ABT-263 (3 µM). The NFκB inhibitor IMD-0354 (10 µM) [215] did not induce cell death alone 
(Figure 2-8C and F), however, it did significantly (P < 0.05) augment ABT-263-mediated apoptosis 
(Figure 2-8C-I) suggesting that IMD-0354 phenocopies the effect of PMCA4 siRNA on ABT-263-







Figure 2-8: NFκB activity in the presence of PMCA1 and PMCA4 siRNA and the effect of 
pharmacological inhibition of NFκB on ABT-263-mediated cell death.  
(A) MDA-MB-231 breast cancer cells stained for NFκB (orange) with DAPI (nuclei, blue) and with 
white arrows depicting translocation of NFκB to the nucleus in the (i) absence of PMA (50 nM), (ii) 
presence of PMA (50 nM), (iii) presence of siPMCA1 and PMA (50 nM) and (iv) presence of siPMCA4 
and PMA (50 nM). (B) Percentage of cells with NFκB nuclear translocation in siRNA transfected cells 
following the addition of PMA (50 nM) normalised to the dimethyl sulfoxide (DMSO) control. (C) The 
proportion of viable cells following IMD-0354 (IMD) and/or ABT-263 (ABT) treatment. (D) The 
proportion of apoptotic cells following IMD-0354 and/or ABT-263 treatment. (E-I) Dot plots of Hoechst 
33342 and propidium iodide fluorescence in cells transfected with siNT or with siPMCA4 in the presence 
of IMD-0354 and/or ABT-263. Each dot plot represents an equal number of total cells (10,000 cells) 
selected at random from three independent experiments. All data were from three independent 
experiments and are presented as mean ± SD where relevant. *P < 0.05, repeated measures two-way 
ANOVA, Bonferroni post-hoc analysis. Scale bar = 25 µm. 
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2.8.9 PMCA1 and PMCA4 in clinical breast cancers 
To determine the distribution of PMCA1 and PMCA4 in breast cancer, we first examined their 
expression in a panel of breast cancer cell lines grown in 3D culture [206]. Expression varied widely 
between cell lines, with variation between the highest and lowest measurements being 18.9- fold and 
12.8-fold for PMCA1 and PMCA4, respectively (Figure 2-9A and B). PMCA1 expression 
measurements were found throughout this range in both luminal and basal cell lines (Figure 2-9A), 
however, PMCA4 was most highly expressed in the basal cell lines (Figure 2-9B, P = 0.007). We 
next evaluated the level of these genes in a cohort of 286 node-negative breast cancer patients 
described by Wang and co-workers [207]. Consistent with the non-significant trend suggested in the 
cell line data (Figure 2-9A), PMCA1 was expressed at higher levels in the ER-positive tumors (Figure 
2-9C, P = 0.007). Median PMCA4 levels were higher in the ER-negative tumors (Figure 2-9D, P = 
0.028). No differences were observed in patient outcomes when tumors were stratified by PMCA1 












Figure 2-9: The expression of PMCA1 and PMCA4 in breast cancer cell lines and clinical samples.  
(A) The relative expression level (log2) of PMCA1 was assessed in a microarray data set consisting of 
luminal (n = 13) and basal (n = 10) breast cancer cell lines grown in three-dimensional culture. (B) 
Relative PMCA4 expression levels in these breast cancer cell lines. (C) The relative expression level of 
PMCA1 was assessed in a microarray data set consisting of oestrogen receptor-negative (n = 77) and -
positive (n = 209) breast tumors. (D) The relative expression level of PMCA4 was assessed in the same 
breast tumor data set. A bar indicates the median, and significance was evaluated using the Mann-
Whitney test. *P > 0.05. (E) Kaplan-Meier analysis of relapse-free survival of the breast cancer patients 
stratified by their tumor levels of PMCA1. (F) Relapse-free survival of breast cancer patients stratified 




Despite the proposed differential contributions of PMCA isoforms in Ca2+ dependent cellular 
processes few studies have evaluated the specific roles of different PMCA isoforms in shaping 
intracellular Ca2+ signals and cellular responses in the same cell types. PMCA1 and PMCA4 have a 
broad tissue distribution and frequently co-express within the same cell [103]. We compared the 
consequences of knockdown of these two PMCA isoforms on [Ca2+]CYT signals generated by various 
Ca2+ mobilising agents. Pronounced effects with PMCA1 knockdown but not with PMCA4 
knockdown were seen on the nature of CPA- and ATP-induced [Ca2+]CYT transients. PMCA1 siRNA 
reduced the rate of [Ca2+]CYT decay and prolonged the ATP Ca
2+ response. Previous studies 
overexpressing PMCA isoforms in CHO cells found that some variants not only alter Ca2+ 
homeostasis within the cytoplasm but also within sub-cellular compartments such as the endoplasmic 
reticulum [117]. Increases in [Ca2+]CYT mediated by sarcoplasmic endoplasmic reticulum Ca
2+-
ATPase inhibitors have been reported to correlate with the calcium content of the ER [216]. Hence, 
increases in the CPA-mediated [Ca2+]CYT transient upon PMCA1 silencing, in addition to being a 
consequence of reduced Ca2+ efflux, may also involve increases in endoplasmic reticulum Ca2+ levels. 
Our study suggests that in MDA-MB-231 breast cancer cells, the PMCA1 isoform is the major 
regulator of global [Ca2+]CYT increases, such as those generated by IP3-mediated Ca
2+ release after 
G-protein coupled receptor activation. The significance of PMCA4 in MDA-MB-231 cells may 
become apparent during very high Ca2+ loads. Indeed, during the high magnitude increases in 
[Ca2+]CYT initiated by 3 µM ionomycin, a contribution for PMCA4 was identified. However, this 
PMCA4 siRNA-mediated effect was not as pronounced as seen with PMCA1 knockdown. This 
finding is also consistent with a predominant role for PMCA1 in the regulation of global [Ca2+]CYT 
signals in this cell type and is consistent with previous studies, demonstrating distinct phenotypes in 
PMCA1 and PMCA4 knockout animals [105, 111, 112]. PMCA1 ablation is lethal during 
embryogenesis, indicative of its vital role in the maintenance of [Ca2+]CYT homeostasis in an array of 
cell types [111]. Although PMCA4 has a broad tissue distribution, PMCA4 null mice reach adulthood 
and exhibit tissue specific phenotypes such as male infertility [105, 111, 112]. These differences 
suggest that PMCA1 adopts a vital housekeeping function by regulating global Ca2+ homeostasis and 
supports the involvement of PMCA4 in Ca2+-dependent signal transduction and cell processes by 
shaping of Ca2+ signals within sub-cellular domains [105, 111, 112].  
We extended our study to examine the consequences of PMCA4 and PMCA1 siRNA on cell death 
in the presence of cell death stimuli. Initial studies, in the absence of any stimuli, showed that the 
viability of MDA-MB-231 breast cancer cells was not affected by PMCA1 or PMCA4 knockdown. 
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In contrast, PMCA2 knockdown produces spinal cord neuronal cell death [193, 217] in the absence 
of external stimuli. Assessment of PMCA1 and PMCA4 knockdown on cell death initiated by 
ionomycin or ABT-263 demonstrated distinct roles for PMCA1 and PMCA4 in the regulation of 
caspase-independent and dependent cell death pathways, respectively. Consistent with the effects 
seen with ionomycin induced [Ca2+]CYT transients, PMCA1 knockdown had a more pronounced effect 
on ionomycin induced cellular necrosis than PMCA4 knockdown. This result further underscores the 
more subtle nature of the change in calcium handling in the cell with PMCA4 knockdown. Previous 
results examining PMCA4 as a sensitiser of cell death in HT-29 colon cancer cells showed that 
PMCA4 silencing does not alter the sensitivity of HT-29 cells to TRAIL or CCCP-induced cell death 
[180]. Reduced expression of another PMCA isoform, PMCA2, augments ionomycin-mediated cell 
death in SH-SY5Y neuroblastoma cells [194]. Whereas its overexpression in T47D breast cancer 
cells bestows resistance to ionomycin-mediated cell death through the attenuation of [Ca2+]CYT 
responses [182].The potential significance of this survival advantage is reflected in the poorer 
prognosis of breast cancer patients with elevated expression of PMCA2 [182]. Our silencing studies 
suggest that modulators of PMCA isoforms involved in global [Ca2+]CYT may sensitise cells to cell 
death stimuli.  
The Bcl-2 inhibitor (ABT-263) used in this study to induce apoptotic cell death in MDA-MB- 231 
breast cancer cells is progressing through clinical trials [192]. A structurally related analogue (ABT-
737) sensitises Bcl-2−expressing breast cancers to chemotherapies [218], highlighting the potential 
for Bcl-2 inhibitors as a therapeutic option for breast cancer. ABT-263-induced cell death was not 
affected by PMCA1 knockdown, but instead was augmented upon reduced expression of PMCA4. 
These distinct differences in the consequences of isoform-specific PMCA knockdown on ionomycin 
and ABT-263 initiated cell death is not totally unexpected, considering these agents activate cell death 
by distinct mechanisms and have markedly different effects on Ca2+ signals. Ionomycin produces 
sustained global increases in [Ca2+]CYT, augmented by PMCA1 siRNA, resulting in Ca
2+ overload 
and cell necrosis. Bcl-2 inhibitors such as ABT-263 initiate caspase-dependent apoptosis by binding 
to and blocking the pro-survival activity of BH3 domains present within Bcl-2 proteins [189-191]. 
Increases in intracellular Ca2+ signals, particularly within subcellular compartments, such as the 
endoplasmic reticulum and mitochondria can modulate Bcl-2- mediated survival pathways [152, 219, 
220]. Our identification of PMCA4 as a modulator of ABT- 263 mediated cell death may be 
analogous to the characterised role of PMCA4 in cardiac cells, where altered PMCA4 expression 
appears to play little role in shaping global [Ca2+]CYT increases [187, 221] yet is an important regulator 
of the Ca2+- dependent transcription factor NFAT influencing outcomes such as cardiac hypertrophy 
[186, 187]. Ca2+- dependent gene transcription critically depends on localisation of Ca2+ signals as 
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well as Ca2+ oscillation frequency and amplitude [209, 210]. Hence PMCA4-mediated regulation of 
transcription may be mediated through the fine-tuning of Ca2+ signals within localised sub-cellular 
domains or through alterations in oscillation frequency. Context dependent modulation of apoptosis 
by PMCAs is reflected in PMCA4 knockout mice studies. Smooth muscle cells from the portal veins 
of PMCA4 knockout mice on a mixed 129/SvJ and Black Swiss background display features of 
apoptosis during in vitro contraction studies [112].  
Our study identified PMCA4 siRNA-mediated inhibition of NFκB nuclear translocation. 
Pharmacological inhibition of NFκB phenocopied the augmentation of ABT-263-mediated apoptosis 
produced by PMCA4 silencing, suggesting that PMCA4 siRNA-augmentation of apoptosis may be 
due to modulation of NFκB. The ability of PMCA4 silencing to inhibit NFκB is significant. The 
activity of NFκB is governed by the nature of Ca2+ signals [209-211]and Ca2+ influx mediated by the 
calcium channel TRPC1 can inhibit NFκB activity in an intestinal epithelial cell line [222]. Breast 
cancers with a poor prognosis are associated with elevated constitutive activity of NFκB [213, 214]. 
Agents that inhibit NFκB are themselves promising anti-tumour modulators for the treatment of 
breast cancers [223, 224] and can enhance the effects of Bcl-2 inhibitors [225]. Our studies comparing 
PMCA1 and PMCA4 in clinical samples suggest that although inhibition of PMCA4 in basal breast 
cancer may be an effective way to augment responsiveness to Bcl-2 inhibitors in breast cancer 
therapy, increases in PMCA4 (or PMCA1) expression are not a cause of general apoptotic resistance 
in breast cancer, as there was no association between PMCA4 (or PMCA1) levels and prognosis.  
In summary, we show that PMCA1 is a major regulator of global Ca2+ homeostasis in MDA-MB- 
231 breast cancer cells and this is associated with an ability of PMCA1 silencing to augment necrotic 
cell death generated by high Ca2+ loads. Although, PMCA4 is not a key regulator of global changes 
in [Ca2+]CYT associated with many stimuli, our study demonstrates a novel relationship between 
PMCA4 and NFκB. Our study highlights isoform diversity between the two almost ubiquitously 
expressed PMCA isoforms (PMCA1 and PMCA4) and identifies PMCA4 as a potential anti-tumor 
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2.11 Additional experiments and data not included in the published manuscript, but relevant to this 
chapter 
2.11.1 Introduction 
The published manuscript achieved PMCA1 and PMCA4 silencing and assessed the consequence of 
this on MDA-MB-231 cell death using ABT-263 and ionomycin to initiate caspase-independent and 
-dependent cell death mechanisms, respectively [227]. Additional experiments presented here, 
describe in more detail the methods and optimisation of the high-throughput cell death assay, and the 
effects of PMCA1 or PMCA4 silencing on the death triggered by ceramide and staurosporine in 
MDA-MB-231 cells. Also examined in more detail are the effects of PMCA-silencing on GPCR-
induced Ca2+ signals initiated by ATP and trypsin, and on store-operated Ca2+ entry upon CPA-
mediated store depletion. 
2.11.2 Materials and methods 
2.11.2.1 Cell culture 
MDA-MB-231 breast cancer cells were cultured as described in section 2.7.1, page 41. 
2.11.2.2 Silencing of PMCA4 and PMCA1 gene expression 
PMCA4 and PMCA1 knockdown in MDA-MB-231 breast cancer cells was achieved according to 
the method in section 2.7.2, page 41. 
2.11.2.3 Real time RT-PCR 
Knockdown of PMCA4 and PMCA1 was confirmed by the real time RT-PCR protocol in section 
2.7.3, page 41. 
2.11.2.4 Cytosolic free calcium measurements 
Cytoplasmic free calcium was measured according to the method 2.7.4, page 42. 
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2.11.2.5 Assessment of cell viability (in more detail) 
 Treatment of MDA-MB-231 breast cancer cells with staurosporine and ceramide  
MDA-MB-231 cells were plated (5 x 103 cells per well) into a 96-well imaging plate, and incubated 
for 24 h. The following day, MDA-MB-231 cells were siRNA transfected as previously described 
(section 2.7.2, page 41) or the culture medium was refreshed. Cells were incubated for a further 72 
hours, and then cell death was initiated by adding staurosporine (Sigma-Aldrich) or ceramide (Sigma-
Aldrich) to confluent cell cultures.  
Staurosporine (at concentrations up to 3 µM) was prepared in phenol red-free media, supplemented 
with 10% FBS from a stock solution of 1 mM in DMSO stored at -22ºC. Ceramide (at concentrations 
up to 300 µM) was also prepared in phenol red-free media, supplemented with 10% FBS, from a 30 
mM stock solution in DMSO stored at -22ºC. 
Figure 2-10 illustrates a typical experiment timeline performed routinely, which incorporates multiple 
techniques including the addition of cell death stimuli along with other methods such as siRNA 
transfection, mRNA isolation, protein isolation, [Ca2+]CYT assessment and cell death analysis. 
 
 Live cell staining with Hoechst 33342 and propidium iodide 
Live cell imaging was performed by a high-throughput approach to assess cell death based on the 
morphological changes, and changes in plasma membrane integrity [208, 228]. The fluorescent dye 
Hoechst 33442 was used to stain cell nuclei and assess changes in nuclear morphology associated 
Figure 2-10: A typical timeline, showing multiple endpoint experiments. 
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with apoptotic cells, which arises from a combination of nuclear condensation, DNA fragmentation 
and subsequent DNA loss [208, 228]. For the assessment of cell death, Hoechst 33342 was added to 
the individual wells of a 96-well imaging plate at a final concentration of 10.0 µg/mL in phenol red-
free media, prepared from a stock solution of 10 mg/mL in water (stored at 4ºC).  
Cells were simultaneously stained with propidium iodide, a fluorescent dye that stains DNA. Unlike 
Hoechst 33442, propidium iodide is cell impermeable and is excluded from apoptotic cells that 
maintain plasma membrane integrity [208, 228]. Therefore, cells positive for propidium iodide at this 
time point are distinguished as necrotic cells, where the plasma membrane has fragmented [208, 228]. 
At extended time points in vitro, apoptotic cells eventually lose their plasma membrane integrity and 
uptake propidium iodide (secondary necrosis) [208, 228]. For the assessesment of cell death, 
propidium iodide was added to the individual wells of a 96-well imaging plate at a final concentration 
of 1.0 µg/mL cells in phenol red-free media supplemented with 10% FBS, prepared from a stock 
solution of 1.0 mg/mL in water (stored at 4ºC).  
 High-content imaging of MDA-MB-231 breast cancer cell death 
For image acquisition, fluorescence was measured using an inverted automated epifluorescent 
microscope. With a 10X objective, four images were automatically acquired per well in the DAPI 
channel for Hoechst 33342 and, in the Cy3 channel for propidium iodide. The multi-wavelength cell 
scoring application module (MetaXpress v3.1.0.83; Molecular Devices Corporation) was used to 
segment cell nuclei, calculate the average Hoechst 33342 integrated intensity and the average 
propidium iodide intensity emitted per cell. Parameters to detect nuclei fluorescence for the DAPI 
channel are shown in Figure 2-11. The same configure settings were applied to the Cy3 channel to 
detect propidium iodide uptake.  Exposure times were automated to a maximum 3000 relative 
fluorescence units per image. Example images and nuclear segmentation for non-treated and 
staurosporine (3 µM) treated MDA-MB-231 breast cancer cells are illustrated in Figure 2-12 and 
Figure 2-13. Fluorescence per cell was exported into Microsoft Office Excel from the multi-
wavelength cell scoring application module (MetaXpress, version 3.1.0.83; Molecular Devices 
Corporation). Viable, apoptotic and necrotic cell populations were identified according to the same 








Figure 2-11: Configure Settings to detect cell nuclei using the multi-wavelength cell scoring application 












Figure 2-12: Example fluorescent images and nuclear segmentation in non-treated MDA-MB-













Figure 2-13: Example fluorescent images and nuclear segmentation in staurosporine (3 µM)-






2.11.2.6 Statistical analysis 
All statistical tests were performed as described in the figure legends using GraphPad Prism, version 





2.11.3.1 Assessment of cell death at two time points  
An initial experiment was performed to assess cell death following 16 h or 48 h incubation with 
staurosporine (STS). The results are presented as dot plots in Figure 2-14A-D. Compared with the 
other treatment protocols (Figure 2-14A-C), MDA-MB-231 cells treated for 48 h with 3 µM STS 
clearly show three cell populations (Figure 2-14D). The third cell population, positioned in the bottom 
left hand side of the dot plot (Figure 2-14D) are propidium iodide negative (intact plasma 
membranes), and have reduced Hoechst 33342 integrated intensity suggesting cells undergoing 
apoptosis [208, 228]. The apoptotic nature of these cells was also evident in Hoechst 33342 intensity 
frequency histograms (Figure 2-14E-F), where a sub-G1 peak was detected in MDA-MB-231 cells 
treated for 48 h with 3 µM STS (Figure 2-14F). The presence of a sub-G1 population is an accepted 
marker of apoptotic cell death [208, 228]. Cell death throughout this thesis, was assessed in MDA-
MB-231 cells after 48 h incubation with various cell death stimuli, because at this time point viable, 









Figure 2-14: MDA-MB-231 breast cancer cell viability after 16 h and 48 h exposure to staurosporine. 
MDA-MB-231 cells were plated (5 x 103 cells per well), and after 96 h incubation, staurosporine (3 µM 
or 0.3 µM, STS) was added to initiate cell death in confluent MDA-MB-231 cells. Cell death was 
assessed following 16 h or 48 h exposure to STS as described in section 2.11.2.5. Dot plots show Hoechst 
33342 and propidium iodide florescence per cell after treatment with (A and B) 0.3 µM STS or (C and 
D) 3 µM STS for either (A and C) 16 h or (B and D) 48 h. Each dot plot represents an equal number of 
total cells (6,434 cells) from a single optimisation experiment performed in triplicate wells. Hoechst 
33342 intensity frequency histograms for cells exposed to (E) 0.3 µM STS or (F) 3 µM STS for 16 h or 




2.11.3.2 Effects of PMCA1 or PMCA4 knockdown on MDA-MB-231 breast cancer cell death triggered by 
ceramide and staurosporine  
Using the high throughput cell death assay aforementioned (section 2.11.3.1, page 74), the ability of 
PMCA1 or PMCA4 silencing in the regulation of MDA-MB-231 cell death was examined. Ceramide 
(C2) and staurosporine (STS) were selected to initiate cell death, because these agents have 
previously been used in studies of PMCA.  
Only a few reports have examined PMCA-mediated regulation of cell death initiated by either 
ceramide or staurosporine. Pinton et al used recombinant PMCA4 expression in HeLa cells to reduce 
[Ca2+]ER, and this protected this cell line against ceramide-induced cell death [152]. Another study 
overexpressed PMCA4 mutants in CHO cells, which were designed not to be cleaved by caspases 
[76]. Expression of these mutant constructs delayed STS-induced apoptosis and was associated with 
altered global [Ca2+]CYT  signals [76].  
In this thesis study, MDA-MB-231 cell death triggered by ceramide at sub-maximum (30 µM) and 
maximum (300 µM) concentrations were not (P > 0.05) altered by either siPMCA1 or siPMCA4 
(Figure 2-15) at the time point assessed.  
Modest, but statistically significant (P < 0.05) effects on cell death were detected when MDA-MB-
231 cells were exposed to STS (Figure 2-16). siPMCA1 protected against STS (0.3 µM) by increasing 
the number of viable cells (Figure 2-16G) and reducing those with necrotic characteristics (Figure 
2-16I). On the other hand, at the maximal STS concentration (3 µM), siPMCA4 increased the number 
of cells undergoing apoptosis (Figure 2-16H). Given the subtle nature of these effects on cell death, 
compared with the data obtained when ABT-263 and ionomycin were used to initiate cell death, these 
results were not the subject of further detailed investigation and were not included in the published 











Figure 2-15: PMCA1 and PMCA4 silencing-mediated effects on cell death in MDA-MB-231 cells 
exposed to ceramide.  
Dot plots of Hoechst 33342 and propidium iodide florescence in cells transfected with (A and D) siNT, 
(B and E) siPMCA4, or (C and F) siPMCA1 following 48 h exposure to (A-C) 30 µM or (D-F) 300 
µM ceramide (C2). Dot plots represent an equal number of total cells (10,000 cells) selected at random 
from three independent experiments. The percentage of (G) viable, (H) apoptotic and (I) necrotic cells 
pooled from three independent experiments. Bar graphs are (mean ± SD). *P < 0.05, repeated measures 










Figure 2-16: PMCA1 and PMCA4 silencing-mediated effects on cell death in MDA-MB-231 cells 
exposed to staurosporine.  
Dot plots of Hoechst 33342 and propidium iodide florescence in cells transfected with (A and D) 
siNT, (B and E) siPMCA4, or (C and F) siPMCA1 following 48 exposure to (A-C) 0.3 µM or (D-
F) 3 µM STS. Dot plots represent an equal number of total cells (10,000 cells) selected at random 
from three independent experiments. The percentage of (G) viable, (H) apoptotic and (I) necrotic 
cells pooled from three independent experiments. Bar graphs are (mean ± SD). *P < 0.05, repeated 
measures two-way ANOVA, Bonferroni post-hoc analysis. 
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2.11.3.3 Consequences of PMCA1 or PMCA4 knockdown on cytoplasmic free calcium increases associated 
with the PAR activator trypsin in MDA-MB-231 breast cancer cells 
The ability of PMCA1 or PMCA4 silencing in shaping ATP Ca2+ signals is presented in section 2.8.2, 
page 47 (published manuscript) [227]. PMCA1 silencing, but not siPMCA4 increased the half peak 
decay time and prolonged the duration of the ATP Ca2+ transient. Extending these studies, the ability 
of siPMCA1 or siPMCA4 in shaping trypsin-induced Ca2+signals was assessed here.  Both ATP and 
trypsin, elicit [Ca2+]CYT increases via IP3 signal transduction, however, they do so by activating 
different GPCRs located at the cell surface. ATP activates P2Y [229], whereas trypsin activates PARs 
(protease activated receptors) [230]. 
Effects of siPMCA1 or siPMCA4 on trypsin Ca2+ signals were determined by assessment of the Ca2+ 
transient parameters peak amplitude (Figure 2-17B), area under the curve (Figure 2-17C), rate of 
[Ca2+]CYT decay (Figure 2-17D) and half peak decay time (Figure 2-17E). PMCA4 knockdown had 
no effect (P > 0.05) on the trypsin Ca2+ transient (Figure 2-17A), which is consistent with the 
conclusion that in some cells PMCA4 can exert effects acting through local Ca2+ signals, rather than 
bulk [Ca2+]CYT [187].  
Although PMCA1 knockdown produced no effect (P > 0.05) on either the peak amplitude (Figure 
2-17B) or area under the curve (Figure 2-17C), silencing of this PMCA isoform significantly (P < 
0.05) reduced the rate of [Ca2+]CYT decay (Figure 2-17D) and delayed the half peak decay time (Figure 
2-17E) of the trypsin Ca2+ signal relative to the siNT control.   
The effect of siPMCA1 on the half peak decay time was also compared between the two GPCR 
activators, ATP versus trypsin (Figure 2-17F). This analysis demonstrated that siPMCA1-mediated 
regulation of the trypsin Ca2+ signal is fairly modest (P > 0.05), when compared to the pronounced 







Figure 2-17: Effect of PMCA1 and PMCA4 silencing on trypsin-induced [Ca2+]CYT increases in MDA-
MB-231 breast cancer cells.  
(A) Trypsin (0.1 µM)-mediated [Ca2+]CYT signals after transfection with siPMCA1, siPMCA4 or siNT 
in the presence of extracellular BAPTA (100 µM) in nominal Ca2+ free medium. Ca2+ traces represent 
relative mean fluorescence. Assessment of the Ca2+ transient parameters (B) peak amplitude (C) area 
under the curve (D) rate of [Ca2+]CYT decay and (E) half peak decay time. (F) Half peak decay time, ATP 
compared with trypsin-induced Ca2+ responses. All data were pooled from three independent 
experiments performed in triplicate. Bar graphs are mean ± SD, and *P < 0.05. (B-E) One-way ANOVA, 
Bonferroni post-hoc analysis, and (F) Two-way ANOVA, Bonferroni post-hoc analysis.  
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2.11.3.4 Effect of CPA on PMCA1 or PMCA4 knockdown during GPCR-linked cytoplasmic free calcium 
increases associated trypsin in MDA-MB-231 breast cancer cells 
SERCA is another Ca2+ pump that contributes to [Ca2+]CYT clearance (section 1.1.2.5, page 6). 
Calcium efflux via SERCA may be a compensatory mechanism for PMCA1 or PMCA4 silencing, 
during trypsin and ATP-induced Ca2+ signals. This possibility was examined using the reversible 
inhibitor CPA to pharmacologically block SERCA activity [231, 232]. 
Trypsin-induced Ca2+ signals were recorded in the absence and presence of CPA in siRNA-
transfected MDA-MB-231 cells (Figure 2-18)  and the Ca2+ transient parameters peak amplitude 
(Figure 2-18C) and half peak decay time (Figure 2-18D) were quantified. The peak amplitudes were 
not significantly (P > 0.05) different between siRNA treatments, and were independent of CPA 
(Figure 2-18C). However, when PMCA1 was downregulated, the addition of CPA significantly (P < 
0.05) delayed the half peak decay time compared with the other treatment combinations (Figure 
2-18B and D). This suggests that SERCA activity may compensate for impaired PMCA1 Ca2+ efflux 






Figure 2-18: Effects of SERCA inhibition on trypsin-induced Ca2+ signals when PMCA1 or PMCA4 
are silenced in MDA-MB-231 breast cancer cells.  
Trypsin-mediated cytosolic [Ca2+] transients were recorded using the Ca2+ indicator Fluo-4AM in 
siRNA-transfected MDA-MB-231 cells (siNT, siPMCA1 or siPMCA4) with extracellular BAPTA 
(100 μM) in nominal Ca2+-free medium. Effects of PMCA1 or PMCA4 silencing on [Ca2+]CYT 
increases in the (A) absence and (B) presence of the SERCA inhibitor CPA (10 μM). Bar graphs 
show the mean ± S.D for the (C) peak amplitude and (D) half peak decay time calculated in the 
absence or presence of CPA. Ca2+ traces represent relative mean fluorescence. All data were obtained 
from three independent experiments (n = 3) performed in triplicate. ***P < 0.001, two-way ANOVA, 
Bonferroni post-hoc analysis. 
87 
 
2.11.3.5 Effect of CPA on PMCA1 or PMCA4 knockdown during GPCR-linked cytoplasmic free calcium 
increases associated with ATP in MDA-MB-231 breast cancer cells 
The potential for SERCA activity to compensate for PMCA1 or PMCA4 silencing was examined for 
ATP-induced Ca2+ signals (Figure 2-19). In the absence and presence of CPA, ATP-induced Ca2+ 
signals were recorded in siRNA-transfected MDA-MB-231 cells and the Ca2+ transient parameters 
peak amplitude (Figure 2-19C) and half peak decay time (Figure 2-19D) were quantified. ATP 
initiated a Ca2+ signal where the peak amplitude was not affected (P > 0.05) by the siRNA treatment 
or by the addition of CPA (Figure 2-19C). When PMCA1 was downregulated, the addition of CPA 
significantly (P < 0.05) delayed the half peak decay time compared with the treatment of siPMCA1 
alone (Figure 2-19D). However, the magnitude of the effect by siPMCA1 was most pronounced (P 
< 0.0001) in the absence of CPA (Figure 2-19D). These results suggest, although SERCA contributes 
to [Ca2+]CYT clearance, PMCA1 is the critical determinant of [Ca
2+]CYT clearance associated with 




Figure 2-19: Effects of SERCA inhibition on ATP-induced Ca2+ signals when PMCA1 or PMCA4 
are silenced in MDA-MB-231 breast cancer cells.   
ATP-mediated cytosolic [Ca2+] transients were recorded using the Ca2+ indicator Fluo-4AM in 
siRNA-transfected MDA-MB-231 cells (siNT, siPMCA1 or siPMCA4) with extracellular BAPTA 
(100 μM) in nominal Ca2+-free medium. Effect of PMCA1 or PMCA4 silencing on [Ca2+]CYT 
increases in the (A) absence and (B) presence of the SERCA inhibitor CPA (10 μM). Bar graphs 
show the mean ± S.D for the (C) peak amplitude and (D) half peak decay time calculated in the 
absence or presence of CPA. Ca2+ traces represent relative mean fluorescence. All data were obtained 
from three independent experiments (n = 3) performed in triplicate. *P < 0.05, **** P < 0.0001, two-
way ANOVA, Bonferroni post-hoc analysis. BAPTA,
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Data from sections 2.11.3.3 - 2.11.3.5 were collectively assessed using the three-way ANOVA 
analysis presented in Figure 2-20, which provides a statistical test for experiments with three factors. 
For these sets of experiments, the factors are siRNA treatment (siNT or siPMCA1), the presence of 
CPA and the GPCR activator (ATP or trypsin). Interpretation of this statistical test is outlined in dot 
points below for the reader’s convenience. 
 siPMCA1 significantly delayed the half peak decay time of the ATP Ca2+ response compared 
with the siNT control, indicating that Ca2+ efflux via PMCA1 is critical for ATP-induced 
[Ca2+]CYT clearance.  
 siPMCA1 did not have a significant effect on the half peak decay time of the trypsin Ca2+ 
response compared with the siNT control, suggesting that Ca2+ efflux via PMCA1 is not 
critical for trypsin-induced [Ca2+]CYT clearance. 
 When PMCA1 is silenced, CPA had a significant effect on the half peak decay time of the 
trypsin Ca2+ response compared with the control treatment siPMCA1 without CPA, 
suggesting that SERCA-mediated Ca2+ efflux compensates for PMCA1 silencing during PAR 
activation.  
 When PMCA1 is silenced, CPA had no effect on the half peak decay time of the ATP Ca2+ 
response compared with the control treatment siPMCA1 without CPA. This data supports the 
view that SERCA-mediated Ca2+ efflux does not compensate for PMCA1 silencing during 
P2Y receptor activation. 
 When PMCA1 is silenced, the effect of CPA on the half peak decay time was not significant 
between the GPCR activators, ATP and trypsin.  
In summary, the data presented in sections 2.11.3.3 - 2.11.3.5 supports the hypothesis that the 
different GPCRs, PAR and P2Y can recruit specific Ca2+ clearance mechanisms to shape intracellular 
Ca2+ signals in MDA-MB-231 breast cancer cells. Mechanistically, this could involve second 
messenger pathways that couple differentially to P2Y versus PAR upon their activation with ATP 
and trypsin, respectively. The recruitment of PMCA pumps by GPCR signal transduction has been 
reported in neurons. ATP and bradykinin activate GPCR receptors and accelerate PMCA-mediated 
Ca2+ efflux by a PKC-dependent mechanism [87].  
The ability of SERCA to compensate for PAR-induced, but not P2Y Ca2+ signals could involve spatial 
constraints, possibly via the PDZ binding domain of PMCA1. One report has demonstrated that 
PMCA1, but not PMCA4, rapidly translocates to the plasma membrane in HT-29 cells following 
muscarinic receptor activation [233]. PMCA1 translocation following activation of this GPCR 
depends on the PDZ-containing protein Na+/H+ exchanger regulatory factor 2 (NHERF), and 
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regulates the rate of Ca2+ efflux [233]. Perhaps a similar relationship between P2Y receptors and 
PMCA1 exists in MDA-MB-231 cells, and is functionally significant in regulating the rate of Ca2+ 
efflux associated with the ATP Ca2+ signal. Differential regulation of PMCA1-mediated Ca2+ efflux 
by different GPCR activators in MDA-MB-231 breast cancer cells requires further examination, in 
particular potential mechanisms (e.g. differential kinase mediated regulation of Ca2+-ATPases and 
















Figure 2-20: Effects of CPA-mediated SERCA inhibition on trypsin and ATP-induced Ca2+ signals in 
MDA-MB-231 breast cancer cells transfected with siNT or siPMCA1.  
Bar graphs show the mean ± S.D for the half peak decay time All data were obtained from three 




2.11.3.6 Consequences of PMCA1 or PMCA4 knockdown on Ca2+ influx via receptor operated calcium entry 
evoked by ATP, trypsin in MDA-MB-231 breast cancer cells 
The consequence of PMCA1 silencing on receptor operated calcium entry (ROCE) was assessed 
using the physiologically relevant GPCR activators trypsin (PAR-2) and ATP (P2Y) (Figure 2-21). 
This assay involved the re-addition of Ca2+ to delineate ROCE as described in other studies [174, 
234]. Following the addition of ATP (Figure 2-21A) or trypsin (Figure 2-21D), the re-addition of 
extracellular Ca2+ stimulated a second phase of Ca2+ entry, and the effect of siPMCA1 or siPMCA4 
on this second phase of Ca2+ entry was determined by assessment of the peak ratio derived by the 
calculation peak two amplitude divided by peak one amplitude [174, 234]. PMCA4 silencing was 
included in these sets of experiments, but had no effect (P > 0.05) on global [Ca2+]CYT associated with 
either receptor-operated (section 2.11.3.6) or store-operated calcium entry (section 2.11.3.7); 
therefore the discussion of these results will focus on the PMCA1 isoform. 
PMCA1 silencing, despite an increase (P < 0.05) in the area under the curve (Figure 2-21B), produced 
no significant effect (P > 0.05) on the peak ratio (Figure 2-21C) associated with ATP-induced ROCE. 
When trypsin was used to stimulate cells, PMCA1 silencing had no effect (P < 0.05) on the area under 
the curve (Figure 2-21E), yet significantly (P < 0.05) reduced the peak ratio (Figure 2-21F).  
The meaning of these results are unclear, however, this data may be consistent with evidence 
presented in this thesis, where increased Ca2+ efflux via SERCA may compensate for PMCA1 
silencing during trypsin-induced Ca2+ signals (section 2.11.3.4, page 85). In this context, the proposed 
increase in SERCA activity, analogous to SERCA overexpression in CHO cells [163], would be 
expected to increase [Ca2+]ER levels. This increase in [Ca
2+]ER levels could be a crucial factor that 
alters the magnitude of ROCE during trypsin-mediated Ca2+ signals when PMCA1 is silenced (Figure 
2-21D). Consistent with this idea, CPA-mediated inhibition of SERCA had no effect (P > 0.05) on 
ATP-induced Ca2+ signals when PMCA1 was silenced (section 2.11.3.5, page 87) and silencing the 
PMCA1 isoform produced no effect (P > 0.05) on ATP-mediated ROCE (Figure 2-21B). Future 
experiments, including those that directly monitor [Ca2+]ER  [235] are required to further investigate 
this hypothesis.  
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Figure 2-21: Effects of PMCA1 or PMCA4 silencing on receptor-operated Ca2+ entry in MDA-MB-
231 breast cancer cells  
 (A) ATP and (D) trypsin-induced [Ca2+]CYT signals were recorded in siRNA-transfected MDA-MB-
231 cells (siNT, siPMCA1 or siPMCA4) using the Ca2+ indicator Fluo-4AM in nominal Ca2+-free 
media in the presence of extracellular BAPTA (100 μM). After the initial [Ca2+]CYT transients 
returned to baseline, the re-addition of Ca2+ stimulated a second phase of Ca2+ entry. Ca2+ traces 
represent relative mean fluorescence. Bar graphs show the mean ± S.D for the calcium transient 
parameters (B and E) peak 1 area under the curve, and the (C and F) peak ratio, derived from peak 
2 amplitude divided by peak 1 amplitude for the Ca2+ signals stimulated by (A-C) 100 μM ATP, or 
(D-E) 0.1 μM trypsin. All data were obtained from three independent experiments (n = 3) performed 
in triplicate, *P < 0.05, repeated measures, one-way ANOVA, Bonferroni post-hoc analysis. 
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2.11.3.7 Consequences of PMCA1 or PMCA4 knockdown on Ca2+ influx via store operated calcium entry in 
MDA-MB-231 breast cancer cells 
The consequence of siPMCA1 on CPA-mediated store-operated calcium entry (SOCE) was also 
assessed (Figure 2-22). As previously reported (section 2.8.2, page 47) siPMCA1 amplified the initial 
CPA-induced Ca2+ signal (Figure 2-22B).  PMCA1 silencing, however, significantly (P < 0.05) 
attenuated the peak ratio associated with CPA-mediated SOCE (Figure 2-22C). This finding could 
be the consequence of the combination, SERCA inhibition plus impaired PMCA1-mediated Ca2+ 
efflux plus a sustained [Ca2+]CYT increase, all of which could reduce SOCE via a negative feedback 
mechanism to prevent intracellular Ca2+ toxicity. A functional interaction between PMCAs and SOCE 
has been reported in primary human aortic myocytes [236]. Orai1 silencing downregulated the Ca2+ 
efflux mechanisms, PMCA1 and NCX1, and this increased the initial CPA-mediated Ca2+ signal, but 





Figure 2-22: Effects of PMCA1 or PMCA4 silencing on store-operated Ca2+ entry in MDA-MB-231 breast 
cancer cells  
 (A) Average CPA-induced [Ca2+]CYT signals were recorded in siRNA-transfected MDA-MB-231 cells (siNT, 
siPMCA1 or siPMCA4) using the Ca2+ indicator Fluo-4AM in nominal Ca2+-free media in the presence of 
extracellular BAPTA (100 μM). After the initial [Ca2+]CYT transients returned to baseline, the re-addition of 
Ca2+ stimulated a second phase of Ca2+ entry. Bar graphs show the mean ± S.D for the calcium transient 
parameters (B) peak 1 area under the curve, and the (C) peak ratio derived from peak 2 amplitude divided by 
peak 1 amplitude.  All data were obtained from three independent experiments (n = 3) performed in triplicate, 




2.12 Chapter Summary 
The work presented in this chapter demonstrates in the MDA-MB-231 breast cancer cell line, that as 
a consequence of isoform-specific knockdown, PMCA1 and PMCA4 have distinct roles in the 
regulation of global calcium signals and in the regulation of caspase-dependent and independent cell 
death. The data presented supports a major role for PMCA1 in the regulation of global calcium signals 
and in the promotion of caspase-independent (necrotic) cell death evoked by the calcium ionophore 
ionomycin, with no effect detected on the sensitivity of caspase-dependent (apoptosis) cell death 
induced by ABT-263. In contrast, this study indicates that PMCA4 is not a key regulator of global 
calcium signals, with modest effects in the augmentation of ionomycin-induced cell death detected 
when compared to PMCA1. However, PMCA4 promoted caspase-dependent (apoptosis) cell death 
mediated by ABT-263. In addition, a novel interaction between NFκB and PMCA4 was identified 
that may underpin the effects of PMCA4 siRNA-mediated promotion in ABT-263-induced cell death. 
The supplementary data reports the consequence of PMCA1 or PMCA4 silencing in the regulation 
of ceramide and staurosporine-induced cell death. Although statistically significant effects upon 
isoform-specific knockdown of PMCA1 and PMCA4 were detected, these effects were modest at the 
time point examined. Work in the supplementary section of this chapter has also begun to explore a 
potential complex activator and isoform dependent regulation of PMCAs in MDA-MB-231 breast 
cancer cells that should be the focus of future studies. In conclusion, this study supports a major 
“housekeeping: role for PMCA1 in global calcium signals and a role for PMCA4 in the regulation of 
calcium-dependent signal transduction pathways, highlighting the anti-tumour potential of PMCA4 
silencing and/or pharmacological inhibition. The following chapter will investigate the significance 




Chapter 3 Assessment of Plasma Membrane Calcium ATPase Isoform 2 Silencing in MDA-MB-231 
Breast Cancer Cells 
3.1 Preface  
The previous chapter demonstrated that PMCA isoforms have distinct effects on cell death pathways 
in breast cancer cells. PMCA4 silencing, but not PMCA1 silencing, promoted caspase-dependent cell 
death initiated by Bcl-2 inhibition using ABT-263 (Navitoclax). Continuing along this theme, the 
current chapter evaluates the effect of another calcium pump isoform, PMCA2 on breast cancer cell 
death.  
Despite aberrant PMCA2 overexpression in human breast cancer cell lines and in clinical breast 
cancer samples [178, 183, 184], the functional consequence of PMCA2 silencing on ABT-263-
mediated cell death is not known. Although very recent silencing studies in breast cancer cell lines 
find that PMCA2 reduces proliferation [183], PMCA2 silencing-mediated effects on cell death have 
focused on the Ca2+ ionophore ionomycin [182, 184]. The ability of PMCA2 silencing to augment 
other death stimuli, of more therapeutic relevance such as Bcl-2 inhibitors has not been examined 
[237, 238]. In this chapter, PMCA2 silencing-mediated effects on global [Ca2+] and on cell death 
initiated with numerous agents including ABT-263 was assessed.  
A manuscript, entitled ‘PMCA2 silencing potentiates MDA-MB-231 breast cancer cell death initiated 
with the Bcl-2 inhibitor ABT-263’ was prepared and submitted to the Journal Biochemical and 
Biophysical Research Communications. The manuscript presents novel research findings that were 
predominantly designed and performed by myself under the supervision of Gregory R Monteith and 
Sarah J Roberts-Thomson and is incorporated into this thesis chapter. Adjustments have been made 






3.2 Chapter Hypothesis 
 PMCA2 silencing sensitises MDA-MB-231 breast cancer cells to cell death responses by 
processing calcium signals  
3.3 Chapter Aims 
 To investigate the functional significance of PMCA2 upregulation in the context of basal 
breast cancer using the MDA-MB-231 breast cancer cell line   
 To inhibit PMCA2 using specific siRNAs to silence expression of the ATB2B gene 
 To study the consequence of PMCA2 silencing on cell death initiated with ionomycin and 
other agents (ABT-263, ceramide and staurosporine) 
 To assess PMCA2 silencing-mediated effects in shaping bulk [Ca2+]CYT increases evoked by 
ATP, trypsin, ionomycin, and CPA 
 
3.4 Highlights 
 PMCA2 silencing can augment ionomycin-mediated cell death  
 Global cytoplasmic calcium signals were not markedly altered by PMCA2 silencing  
 PMCA2 silencing sensitised cells to apoptotic cell death initiated with ABT-263  





PMCA2 overexpression in some breast cancers suggests that this calcium pump isoform may play a 
role in breast pathophysiology. To investigate PMCA2 as a potential drug target for breast cancer 
therapy, we assessed the functional consequence of PMCA2 silencing on cell death pathways and 
calcium signals in the basal-like MDA-MB-231 breast cancer cell line. Silencing PMCA2 expression 
alone has no effect on MDA-MB-231 cell viability, however, PMCA2 silencing promotes calcium-
induced cell death initiated with the calcium ionophore ionomycin. Assessment of cytoplasmic 
calcium responses generated with various agents including ionomycin demonstrates that in MDA-
MB-231 cells, PMCA2 does not play a major role in shaping global calcium signals. We also 
examined the ability of PMCA2 silencing to modulate caspase-dependent cell death triggered by a 
Bcl-2 inhibitor that is in clinical development for the treatment of various cancers, ABT-263 
(Navitoclax). Despite the lack of effect on global calcium responses, PMCA2 silencing augmented 
Bcl-2 inhibitor (ABT-263)-mediated MDA-MB-231 breast cancer cell death. These studies provide 
evidence that PMCA2 inhibitors could sensitise PMCA2-positive breast cancers to cell death 
initiators that work through mechanisms involving the Bcl-2 survival pathway.   
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3.6 Introduction  
The calcium efflux pump, plasma membrane calcium ATPase (PMCA) isoform 2 has been proposed 
as potential target for the treatment of some breast cancers [239]. Aberrant overexpression of PMCA2 
in some breast cancer cell lines [178] and the positive correlation between PMCA2 protein expression 
and tumor characteristics including tumor grade and HER2 status in clinical breast cancer cases [182] 
suggests that PMCA2 could facilitate disease progression [182]. More recently, PMCA2 mRNA 
levels were assessed in breast cancers grouped by molecular subtype [183]. PMCA2 mRNA was 
higher in basal breast cancers compared to HER2, luminal A and luminal B subtypes [183]. Although 
a feature of some breast cancers, only a few studies have evaluated the functional significance of 
PMCA2 upregulation in the context of cell death in breast cancer; and detailed assessment of PMCA2 
through overexpression or silencing techniques has been limited to luminal-like breast cancer cell 
lines that express at least one hormone receptor (oestrogen or progesterone receptors) or those with 
HER2 amplification [182, 184].  Heterologous PMCA2 expression in T47D cells attenuates global 
cytosolic free Ca2+ levels ([Ca2+]CYT) and protects T47D cells from calcium-induced cell death 
initiated with ionomycin [182]. Assessment of PMCA2 silencing in the context of HER2 positive 
breast cancers has been examined in the SKBR3 and BT474 breast cancer cell lines [184], both of 
which are positive for HER2 amplification [240].  PMCA2 knockdown in SKBR3 promotes 
ionomycin cell death and downregulates HER2 signaling [184].  
Until recently the consequence of PMCA2 silencing in a basal-like breast cancer cell line had not 
been evaluated. One cell line widely used as a model for basal breast cancer subtypes, which overlaps 
with breast cancers that are negative for hormone receptor expression and HER2 amplification is the 
MDA-MB-231 breast cancer cell line [240]. Studies in this cell line demonstrate PMCA2 silencing 
attenuates proliferation and potentiates the anti-proliferative action of low concentrations of the 
cytotoxic doxorubicin [183]. Since neither PMCA1 nor PMCA4 silencing produced effects on cell 
proliferation, PMCA-mediated regulation of MDA-MB-231 cell growth appears to be PMCA2 
specific in this breast cancer cell line. This and other studies emphasize that PMCA isoforms are 
functionally distinct, even when expressed in the same cell type.  
PMCA2 silencing-mediated effects on breast cancer cell death have focused on ionomycin [184], 
which can trigger cell death through sustained [Ca2+]CYT increases of high magnitude [6, 184, 227]. 
The consequence of PMCA2 knockdown on B-cell lymphoma-2 (Bcl-2) inhibitor-mediated apoptosis 
has not been assessed. Bcl-2 is a pro-survival oncogene overexpressed in 75% of breast cancers [237]. 
ABT-263 (Navitoclax) is a Bcl-2 inhibitor undergoing clinical trial assessment for various cancer 
indications including lymphoma, prostate and colon cancer [238]. Studies of PMCA knockdown-
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mediated effects on Bcl-2 inhibitor (ABT-263)-induced apoptosis have only so far been examined 
for PMCA1 and PMCA4 isoforms [227]. PMCA1 regulates global [Ca2+]CYT signals, however, 
PMCA1 knockdown had no effect on Bcl-2 inhibitor-mediated cell death [227]. Whereas, PMCA4 
silencing promoted apoptosis in MDA-MB-231 cells initiated with the Bcl-2 inhibitor ABT-263, 
without significant effects on global calcium signals [227]. Isoform-specific PMCA knockdown in 
MDA-MB-231 cells produces very different outcomes on [Ca2+]CYT, and on the cancer-relevant 
pathways proliferation and apoptosis. However, the consequence of PMCA2 silencing on Bcl-2 
inhibitor-mediated cell death has not been evaluated. 
In this current study, we examined the effects of PMCA2 silencing in MDA-MB-231 breast cancer 
cells on global calcium signals and in the modulation of cell death initiated with ionomycin and the 
Bcl-2 inhibitor ABT-263. Our findings suggest that PMCA2 inhibitors, in combination with anti-
cancer agents that work through the Bcl-2 pathway, could be effective for the treatment of PMCA2-
positive breast cancers; including breast cancer cases that are typically unresponsive to targeted 
therapies such as those targeting HER2 (e.g. trastuzumab) and the oestrogen receptor (e.g. tamoxifen) 




3.7 Material and Methods  
3.7.1 Cell culture 
Human MDA-MB- 231 breast cancer cells (American Type Culture Collection, Rockville, MD, 
USA) were maintained in high glucose DMEM (D6546, Sigma Aldrich, St Louis, MO, USA) 
containing 10% fetal bovine serum and 4 mM L-glutamine (25030081, Invitrogen, Carlsbad, CA, 
USA) at 37°C/5% CO2 in a humidified air incubator. All cultures were periodically screened for 
mycoplasma infection. 
3.7.2 RNA interference  
PMCA2 levels were downregulated in MDA-MB-231 cells according to methods previously 
described [183, 227] using ON-TARGETplus™ Human SMARTpool siRNAs (Thermo Scientific, 
Waltham, MA, USA). These siRNAs consist of four pooled sequences rationally designed to 
minimise off-target effects [195, 196, 241]. The ON-TARGETplus™ Human SMARTpool siRNA 
sequences used were PMCA2 (siPMCA2, L-006116-00) and the non-targeting control siRNA (siNT, 
D-001810-10).  For all experiments knockdown of PMCA2 (>70%) was confirmed by real time RT-
PCR at 120 h post-siRNA transfection. 
3.7.3 Real time RT-PCR 
At 48 h or 120 h post-siRNA transfection quantitative real time RT-PCR was performed as previously 
reported [227]. Total RNA was isolated (74134, RNeasy Plus mini kit; Qiagen, Hilden, Germany) 
and then reverse transcribed (205111, Omniscript RT kit; Qiagen). The target cDNAs were amplified 
using the TaqMan Fast Universal PCR Master Mix (4352043, Applied Biosystems, Carlsbad, CA, 
USA) and TaqMan Gene Expression assays (PMCA2, Hs00155975_m1 and 18S rRNA, 4319413E; 
Applied Biosystems) under universal cycling conditions with a StepOnePlus real time PCR system 
(Applied Biosystems). Target mRNA levels were quantified by the comparative Ct method as 




3.7.4 Cytoplasmic free calcium measurements 
At 120 h post-siRNA transfection, media was removed from MDA-MB-231 cells and replaced with 
culture medium containing Fluo-4 AM (4 μM; Molecular Probes, Eugene, OR, USA) or Fluo-4FF 
AM (4 μM; Molecular Probes). Using these Ca2+ indicators changes in [Ca2+]CYT were recorded using 
a fluorescence imaging plate reader [198] (FLIPRTETRA, Molecular Devices, Sunnyvale, CA, USA) 
as previously described [227]. To assess relative [Ca2+]CYT, fluorescence values were normalised to 
initial baseline values. 
3.7.5  Assessment of cell viability 
MDA-MB-231 cells were siRNA-transfected for 72 h, and then treated for an additional 48 h with 
ionomycin (Enzo Life Sciences, Farmingdale, NY, USA), ABT-263 (S1001, Selleckchem, Houston, 
TX, USA), or dimethyl sulfoxide (up to 0.33%). Cells were then stained with Hoechst 33342 (10 
μg/mL; H3570, Invitrogen) and propidium iodide (1 μg/mL; P3566, Invitrogen) at 37°C for 15 min 
and cell death assessed using an ImageXpress micro automated epifluorescence microscope 
(Molecular Devices Corporation) and the multi-wavelength cell scoring application module 
(MetaXpress v3.1.0.83; Molecular Devices) as previously described [227]. Cell viability was 
determined by combining propidium iodide positive cells and those identified as apoptotic to 
calculate the total number of dead cells [227]. 
3.7.6 Statistical analysis 
All statistical tests were performed as described in the figure legends using GraphPad Prism (version 




3.8 Results  
3.8.1 PMCA2 silencing and consequences on MDA-MB-231 breast cancer cell viability in the absence 
and presence of the calcium ionophore ionomycin  
To explore the functional significance of PMCA2 in a basal like breast cancer cell line, we silenced 
PMCA2 gene expression in MDA-MB-231 cells. Non-targeting (siNT) and PMCA2 (siPMCA2) 
siRNAs were transfected into MDA-MB-231 cells and PMCA2 silencing was confirmed by mRNA 
analysis. Cells transfected with siPMCA2 showed a significant (P < 0.05) downregulation in PMCA2 
mRNA, at both time points 48 h and 120 h post-transfection, compared with siNT controls (Figure 
3-1A).   
Using this model, we assessed siPMCA2-mediated regulation of cell viability. With no stimulus, 
PMCA2 silencing had no effect on MDA-MB-231 cell viability compared with the siNT control 
(Figure 3-1B and C). However, in the presence of sub-maximum (3 µM) ionomycin, siPMCA2 
significantly (P < 0.05) reduced cell viability compared to the siNT control (Figure 3-1C). No 
measurable effect (P > 0.05) on cell viability was detected at the maximum (10 μM) ionomycin 
concentration, comparing siPMCA2 with the siNT control (Figure 3-1C). These findings suggest that 
PMCA2 silencing without a stimulus does not trigger cell death, although, siPMCA2 can modestly 




Figure 3-1 PMCA2 silencing in MDA-MB-231 breast cancer cells and the consequence of silencing on cell viability and ionomycin-induced cell death.   
PMCA2 silencing in MDA-MB-231 breast cancer cells and the consequence of silencing on cell viability and ionomycin-induced cell death.  PMCA2 
expression was silenced using siRNA and then cell viability assessed in the absence and presence of the calcium ionophore ionomycin, comparing 
siPMCA2 with the siNT control.  (A) PMCA2 mRNA levels 48 h and 120 h post-siRNA, *P < 0.05, two-way ANOVA, Bonferroni post hoc analysis. 
(B) Representative dot plots show cell viability with siNT and siPMCA2. Dot plots are Hoechst 33342 and propidium iodide fluorescence measured in 
random cells (10 000 cells/dot plot) selected from three experiments (n = 3). (C)  Cell viability following siNT and siPMCA2 transfection, either in the 
absence (0 µM) or presence of ionomycin (3 µM or 10 µM). *P < 0.05, repeated-measures, two-way ANOVA, Bonferroni post hoc analysis. All bar 




3.8.2 Effects of PMCA2 silencing on ionomycin-induced cytoplasmic calcium signals in MDA-MB-231 
cells 
To further evaluate the relationship between PMCA2 and ionomycin, high magnitude [Ca2+]CYT 
signals generated using ionomycin were measured in siRNA-transfected MDA-MB-231 cells using 
the low affinity Ca2+ indicator Fluo-4FF AM, in the presence of extracellular calcium.  As reflected 
by assessment of the calcium transient parameter, area under the curve (Figure 3-2B and D), calcium 
signals at sub-maximum (3 μM; Figure 3-2A and B) and maximum (10 μM; Figure 3-2C and D) 
ionomycin concentrations were not significantly (P > 0.05) altered by PMCA2 silencing, compared 
with the siNT controls. These data indicate that siPMCA2 does not elicit profound effects on 





Figure 3-2. Effect of PMCA2 silencing on ionomycin-induced calcium signals in MDA-MB-231 
breast cancer cells.  
[Ca2+]CYT signals generated with the calcium ionophore ionomycin at (A) 3 µM and (C) 10 µM 
were recorded in cells transfected with siPMCA2 or siNT. Calcium traces depict mean relative 
[Ca2+]CYT fluorescence. Area under the curve for the (B) 3 μM and (D) 10 μM ionomycin Ca2+ 
signals. Bar graphs are mean ± S.D, unpaired two-tailed student’s t test. All data were pooled 




3.8.3 Consequences of PMCA2 silencing on CPA, ATP and trypsin induced calcium signals in MDA-
MB-231 breast cancer cells 
The potential of PMCA2 to shape bulk [Ca2+]CYT increases of more moderate magnitudes was also 
examined using the high affinity Ca2+ indicator Fluo-4 AM. In siRNA-transfected MDA-MB-231 
cells, [Ca2+]CYT signals were monitored in the presence of the Ca
2+ chelator BAPTA (100 µM) in 
nominal free Ca2+ physiological salt solution, following the addition of the sarco/endoplasmic 
reticulum Ca2+ ATPase (SERCA) inhibitor cyclopiazonic acid (CPA, 10 μM, Figure 3-3A), the 
purinergic receptor agonist ATP (100 μM, Figure 3-3D) or the protease activated receptor activator 
trypsin (0.1 µM, Figure 3-3G). Assessment of the calcium transient parameters, half peak decay time 
(Figure 3-3B, E and H) and area under the curve (Figure 3-3C, F and I) demonstrated that compared 
with the siNT control, PMCA2 silencing did not significantly (P > 0.05) shape Ca2+ responses 
associated with either CPA (Figure 3-3B and C), ATP (Figure 3-3E and F), or trypsin (Figure 3-3H 
and I). These data support the conclusion that PMCA2 in MDA-MB-231 cells is not a key regulator 
of bulk [Ca2+]CYT signals. 
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Figure 3-3: Effect of PMCA2 silencing on various agents that increase global cytoplasmic free calcium.  
siRNA-transfected MDA-MB-231 breast cancer cells were treated with the calcium mobilising agents 
(A) CPA (10 μM), (D) ATP (100 μM), and (G) trypsin (0.1 µM) in the presence of extracellular BAPTA 
(100 μM) in nominal free Ca2+. Calcium traces depict mean relative [Ca2+]CYT. Half peak decay time 
calculated for the (B) CPA, (E) ATP and (H) trypsin Ca2+ responses. Area under the curve calculated for 
the (C) CPA, (F) ATP and (I) trypsin responses. Bar graphs quantitate calcium transient parameters as 
mean ± S.D. *P < 0.05, unpaired two-tailed student’s t test. All data were pooled from three independent 
experiments (n = 3), performed in triplicate wells. 
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3.8.4 Regulation of ABT-263-mediated cell death by PMCA2 silencing in MDA-MB-231 cells 
PMCA4 potentiates caspase-dependent cell death, initiated with the Bcl-2 inhibitor ABT-263 in 
MDA-MB-231 cells [227]. We therefore investigated whether PMCA2 silencing modulates ABT-
263-mediated death responses. At 1 µM, ABT-263-mediated cell death was almost doubled by 
knocking down PMCA2 (mean ± S.D.; 36 ± 11% for the siNT control versus 68 ± 5% for siPMCA2; 
Figure 3-4A and B). To characterise this effect, cell viability was measured in siRNA-transfected 
MDA-MB-231 cells, treated at increasing concentrations of the Bcl-2 inhibitor ABT-263 (0.1 – 10 
μM; Figure 3-4C). Compared to the siNT control, siPMCA2 significantly (P < 0.05) reduced cell 
viability in the presence of ABT-263. This was evidenced by a 4.5-fold leftward shift in the half 
maximal inhibitory concentration (IC50), from 2.2 µM for siNT versus 0.48 µM for siPMCA2. These 
data show that PMCA2 silencing sensitises the MDA-MB-231 cell line to caspase-dependent ABT-









Figure 3-4: Effects of PMCA2 silencing of MDA-MB-231 breast cancer cell death initiated by the Bcl-2 
inhibitor ABT-263.  
(A) Representative dot plots are Hoechst 33342 and propidium iodide fluorescence detected in cells 
transfected with siNT or siPMCA2 and treated with 1 μM ABT-263. Dot plots show an equal cell number 
(10,000 cells/dot plot), randomly selected from three independent experiments (n = 3). (B) Effect of 
siPMCA2 and siNT on cell death at 1 µM ABT-263. Bar graph shows mean ± S.D, *P < 0.05, paired two-
tailed student’s t test (C) Concentration-response curves show the effect of siNT and siPMCA2 on cell death 
initiated at various ABT-263 concentrations (0.01 – 10 µM).  Values plotted are mean ± S.D, *P < 0.05, 
siNT compared to siPMCA2 at the indicated ABT-263 concentration, repeated measures, two-way 
ANOVA, Bonferroni post hoc test. Data were obtained from three independent experiments (n = 3), 
performed in triplicate wells. 
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3.9 Discussion  
This report extends previous studies of PMCA1 and PMCA4 in MDA-MB-231 breast cancer cells 
[227], and evaluated PMCA2-mediated effects on cell death and calcium signaling in this cell line 
using targeted siRNAs to silence PMCA2 gene expression. Initial experiments showed that PMCA2 
silencing alone does not alter MDA-MB-231 cell viability. Since PMCA isoforms are known 
regulators of calcium-induced cell death [182, 184, 227], we assessed the consequence of PMCA2 
silencing on ionomycin death responses. Our results indicated that PMCA2 silencing modestly 
promoted ionomycin MDA-MB-231 cell death at submaximal concentrations. This is consistent with 
other studies that demonstrate through overexpression or downregulation systems, that PMCA2 
modulates ionomycin cell death in the T47D and SK-Br-3 breast cancer cell lines [182, 184].  
We found that PMCA2 is not a key regulator of global [Ca2+]CYT signals generated with ionomycin, 
or  those associated with physiologically relevant mediators ATP and trypsin, which increase 
[Ca2+]CYT via G protein-coupled receptor activation. This result may be surprising, however, not 
entirely unexpected because PMCA2 expression is relatively low in MDA-MB-231 cells compared 
with other isoforms [183]. PMCA1, which is the predominate isoform expressed in MDA-MB-231 
cells, when knocked down has a pronounced effect on the shape of global [Ca2+]CYT signals generated 
with many stimuli [183, 227]. 
Although reported for PMCA1 and PMCA4 [227], PMCA2-mediated regulation of Bcl-2 inhibitor-
mediated cell death has not been previously examined. Our data demonstrated that despite no 
significant effects on global calcium signaling, PMCA2 silencing augmented ABT-263-mediated 
MDA-MB-231 cell death. This finding is analogous to PMCA4, where knocking down PMCA4 
sensitised MDA-MB-231 cells to ABT-263 initiated cell death, independent of global calcium [227]. 
While PMCA4 and PMCA2 distinctly regulate cell proliferation [183], these isoforms appear to have 
related effects on the Bcl-2 survival pathway. 
Growing evidence indicates that PMCA isoforms regulate calcium-dependent signal transduction 
through protein-protein interactions, and fine-tuning of localised calcium signals [183, 187, 221, 227, 
242]. The ability for PMCA2 silencing to promote ABT-263-mediated cell death, is likely the result 
of disrupting pro-survival protein-protein interactions through processing localised calcium signals. 
PMCA2 interacts with the calcium-dependent signaling molecule calcineurin, and this interaction can 
regulate cell death [186, 243]. Preventing the interaction between PMCA2 and calciuneurin, 
upregulates pro-apoptotic protein expression via the nuclear factor of activated T cell (NFAT) 
transcriptional pathway [243]. This intervention reduces cell viability across a panel of breast cancer 
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cell lines, and enhances paclitaxel-induced cytotoxicity in MCF-7 and ZR-75-1 breast cancer cells 
[243]. PMCA2-mediated regulation of the Bcl-2 survival pathway may also involve another calcium-
dependent transcription factor nuclear factor-kappa B (NFκB). We previously demonstrated that 
PMCA4 silencing inhibits NFκB nuclear translocation, and that pharmacological inhibition of NFκB 
phenocopies the promotion of ABT-263-mediated cell death produced by PMCA4 silencing [227]. 
Mechanistic studies are now required to clarify the importance of the calcineurin/NFAT and/or NFκB 
transcription factor pathways in the promotion of Bcl-2 inhibitor cell death produced by PMCA2 
silencing in MDA-MB-231 breast cancer cells.  
In conclusion, this study provides further evidence supporting the view that PMCA2 inhibitors may 
be a novel treatment for PMCA2-positive breast cancers. This approach may be most effective in 
basal-like subtypes of breast cancers when delivered in combination with agents that initiate cell 
death via effects on the Bcl-2 cell survival pathway. 
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3.11 Additional experiments relevant to chapter three, but not included in the manuscript  
3.11.1 Introduction 
The data submitted for publication in the journal of Biochemical and Biophysical Research 
Communications illustrate that in MDA-MB-231 breast cancer cells, PMCA2 is not a major regulator 
of global [Ca2+]CYT and PMCA2 silencing promotes cell death associated with ionomycin and via the 
inhibition of Bcl-2.  Additional experiments presented here, examine in more detail PMCA2 mRNA 
expression in MDA-MB-231 cells, and assessed the consequence of PMCA2 silencing on other death 
stimuli, cell number, and on calcium influx associated with CPA-induced Ca2+ store depletion, and 
via GPCR activation using ATP and trypsin. 
3.11.2 Materials and methods 
3.11.2.1 Cell culture  
MDA-MB-231 breast cancer cells were cultured as described in the prepared manuscript, section 
3.7.1, page 102. 
3.11.2.2 RNA interference 
Specific knockdown of PMCA isoform 2 was performed as described in the manuscript, section 3.7.2, 
page 102. 
3.11.2.3 Real time RT-PCR 
PMCA1, PMCA2 and PMCA4 mRNA levels were measured as described in the manuscript, section 
3.7.3, page 102. Additional TaqMan Gene Expression assays were used to quantify PMCA4 
(Hs00608066_m1, Applied Biosystems) and PMCA1 (Hs00155949_m1, Applied Biosystems). 
3.11.2.4 Cell enumeration 
At 120 h post-siRNA transfection, media was removed and MDA-MB-231 cells were assessed for 
cell death as detailed in section 3.7.5, page 103. Cells were enumerated in siNT and siPMCA2 treated 
cells, not exposed to a death stimulus. Cell number was measured using the multi-wavelength cell 
scoring application module, counting the number of nuclei stained with Hoechst 33342 (MetaXpress 
v3.1.0.83; Molecular Devices). 
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3.11.2.5 Cytosolic free calcium measurements 
Cytoplasmic free calcium was measured according to the method in section 3.7.4, page 103. 
3.11.2.6 Statistical analysis 
All statistical tests were performed as described in the figure legends using GraphPad Prism (version 




3.11.3 Results and discussion 
3.11.3.1 Relative PMCA2 expression in MDA-MB-231 breast cancer cells 
PMCA2 mRNA levels in MDA-MB-231 cells were assessed using real time RT-PCR. PMCA2 
mRNA increased significantly (P < 0.05) with increasing cell confluence (Figure 3-5A). This result 
suggests that PMCA2 is upregulated with increasing cell density, which may relate to elevated 
PMCA2 levels detected in more advanced breast cancer cases that are characteristically larger, and 
higher grade [182]. Despite this increase in PMCA2 mRNA, analysis of relative PMCA isoform 
expression in confluent cultures indicated that PMCA1 is the primary transcript expressed in this cell 
line (Figure 3-5B).  
PMCA2 upregulation in the lactating mammary gland exceeds the expression levels of other PMCA 
isoforms [58, 108]. This difference of expression in the lactating mammary gland versus breast 
cancer, may reflect the different function of PMCA2 in the physiological versus pathological setting. 
PMCA2 in the lactating mammary gland is critical for Ca2+ secretion and milk production [58, 59, 
107, 108]. Whereas, PMCA2 expression in breast cancer, where the goal is not milk production, 
appears to confer the resistance to death stimuli [182-184, 243]. Detailed assessment of PMCA2 
silencing on other cancer-relevant pathways such as proliferation and/or metastasis are required to 




Figure 3-5: Relative PMCA2 expression in MDA-MB-231 breast cancer cells. 
Assessment of PMCA2 mRNA levels in MDA-MB-231 cells transfected for 120 h with ON-
TARGETplus siRNA. (A) Changes in PMCA2 mRNA expression in sub-confluent and confluent cell 
cultures.  (B) Expression of PMCA2, PMCA4 and PMCA1 mRNA presented relative to PMCA2 
mRNA levels in confluent cultures. Bar graphs show mean ± S.D, and were pooled from three 










3.11.3.2 PMCA2 silencing-mediated effects on cell enumeration in MDA-MB-231 breast cancer cells  
PMCA2 upregulation in the pathological setting of breast cancer could be tailored to promote another 
cancer hallmark, increased cell proliferation [119, 171]. Therefore, the siPMCA2-mediated 
regulation of cell number was examined. Knocking down PMCA2 significantly (P < 0.05) reduced 
MDA-MB-231 cell numbers compared with the siNT control (Figure 3-6A). This result is consistent 
with a recent study, which I co-authored that showed PMCA2 downregulation, but not PMCA1 or 
PMCA4 silencing, attenuates MDA-MB-231 cell proliferation [183]. Hence, PMCA2 may be  the 
responsible isoform that when inhibited attenuates MCF-7 breast cancer cell proliferation via the non-
selective inhibition of all PMCA isoforms via antisense [185]. PMCA2 inhibitors, along with the 







Figure 3-6: PMCA2 silencing-mediated effects on MDA-MB-231 breast cancer cell number. 
(A) Bar graph of average cell number shows reduced MDA-MB-231 cell number with siRNA-
transfection, compared with the siNT control. Data are obtained from three independent experiments 




3.11.3.3 Consequences of PMCA2 silencing on Ca2+ entry following intracellular store depletion associated 
with CPA, ATP and trypsin in MDA-MB-231 breast cancer cells 
The consequence of PMCA2 silencing on Ca2+ entry following intracellular store depletion associated 
with the GPCR activators ATP (100 µM) and trypsin (0.1 μM) and with the SERCA inhibitor CPA 
(10 μM) was examined in siRNA-transfected MDA-MB-231 cells in nominal free Ca2+ physiological 
salt solution, containing BAPTA (100 µM, Figure 3-7). After the initial [Ca2+]CYT Ca
2+ transients 
returned to baseline, a second phase of [Ca2+]CYT increase was monitored following the re-addition 
of external Ca2+ (Figure 3-7A, C and E). Assessment of the peak ratio calculated by dividing the 
second peak amplitude with the first peak amplitude [29, 234] was used to determine PMCA2-
silencing mediated effects on ROCE (Figure 3-7B and D) and on SOCE (Figure 3-7F). 
PMCA2 knockdown produced no significant (P > 0.05) effect on the peak ratio associated with the 
Ca2+ signals generated using ATP (Figure 3-7B) or trypsin (Figure 3-7D) or CPA (Figure 3-7F). 
Therefore, PMCA2 is not a major regulator of bulk [Ca2+]CYT increases associated with SOCE 







Figure 3-7: Effects of PMCA2 silencing on receptor-operated and store-operated Ca2+ entry in MDA-
MB-231 breast cancer cells  
 (A) ATP, (C) trypsin and (E) CPA-induced [Ca2+]CYT signals were recorded in siRNA-transfected 
MDA-MB-231 cells (siNT or siPMCA2) using the Ca2+ indicator Fluo-4AM in nominal Ca2+-free media 
in the presence of extracellular BAPTA (100 μM). After the initial [Ca2+]CYT transients returned to 
baseline, the re-addition of Ca2+ stimulated a second phase of Ca2+ entry. Ca2+ traces represent relative 
mean fluorescence. Bar graphs show the mean ± S.D for the peak ratio calculated for the Ca2+ signals 
generated with (B) 100 μM ATP, (D) 0.1 μM trypsin, and (F) 10 μM CPA. All data were obtained from 




3.11.4 Chapter summary 
PMCA2 is proposed as a drug target for breast cancer therapies [183, 184, 239, 244]. Supporting this 
view, PMCA2 expression has a restricted tissue distribution, with high amounts in the central nervous 
system [103], and appears to be differentially expressed in the mammary gland [58, 108]. Although 
undetected or at very low levels in normal, non-lactating mammary glands, PMCA2 is overexpressed 
in a significant amount of human breast cancers cases [182, 183].  The utility of PMCA2 inhibitors 
for therapeutic agent development, however, requires validation studies. To address this, the 
functional significance of PMCA2 silencing on calcium signals and on the cancer-relevant pathways 
cell death and proliferation was examined in MDA-MB-231 breast cancer cells.  
The bulk of the research findings were submitted for publication in the journal BBRC, and focused 
on PMCA2 silencing-mediated regulation of cell death. PMCA2 silencing sensitised MDA-MB-231 
breast cancer cells to ionomycin toxicity and Bcl-2 inhibitor-mediated apoptosis. The ability of 
PMCA2 silencing to promote Bcl-2 inhibitor (ABT-263)-mediated cell death is significant. Bcl-2 is 
an oncogene that inhibits cell death and protects cells against a broad range of cytotoxic agents 
including anti-cancer drugs [238]. The Bcl-2 inhibitors ABT-737, ABT-199, along with the inhibitor 
used in these thesis studies ABT-263, are in clinical trial assessment for various cancer indications 
[238]. Approximately 75% of breast cancers express Bcl-2, and preclinical assessment of Bcl-2 
inhibitors showed efficacy in breast cancer [237, 238].  
Antisense-mediated inhibition of PMCA isoforms attenuates MCF-7 breast cancer cell proliferation 
[185]. PMCA2 silencing reduced MDA-MB-231 cell number. A recent study co-authored by me, in 
the same cell line, also detected the anti-proliferative effect of PMCA2 and demonstrated that 
knockdown of other PMCA isoforms (PMCA1/4) has no effect on proliferation [183]. Although these 
results need confirmation studies in other breast cancer cells, and in the presence of agents that either 
promote or inhibit proliferation, therapeutic targeting of PMCA2 in PMCA2-positive breast cancers 
could combat this disease through the promotion of cell death and suppressing cell proliferation. 
In contrast with MDA-MB-231 breast cancer cells, where PMCA2 was expressed at relatively low 
levels compared with PMCA1 and PMCA4; PMCA2 expression in lactation supersedes that of other 
PMCA isoforms (PMCA1/4). These differences in expression may reflect the different functional 
roles of PMCA2 in the lactating mammary gland versus breast cancer.  Mammary secretory cells in 
lactation transport Ca2+ from the blood to milk, and studies in rodents demonstrate PMCA2 is critical 
for the secretion of Ca2+ into milk, protects against calcium toxicity, and prevents early involution 
and milk stasis [58, 59, 107, 108]. Rather than fulfilling the physiological demands associated with 
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lactation and milk production, aberrant PMCA2 in MDA-MB-231 cells appears to protect against 
death stimuli and promote cell proliferation [182-184]. PMCA2-mediated regulation of Bcl-2 
survival pathways and cell proliferation, may therefore be relevant even when PMCA2 is not the 
predominant isoform expressed.  
Overall, this chapter demonstrates that PMCA2 inhibitors could represent a therapeutic option for the 




Chapter 4 Assessment of Mitochondrial Calcium Uniporter (MCU) Silencing in the MDA-MB-231 
Breast Cancer Cell Line 
4.1 Preface 
Chapters two and three demonstrated that isoform-specific silencing of PMCAs effects cell death 
independently of global [Ca2+]CYT. Although there is precedent for PMCA pumps to influence cell 
events via localised calcium signals within cytoplasmic micro-domains, overexpression studies show 
that PMCA isoforms can also modulate calcium signals within sub-cellular compartments. Because 
mitochondria orchestrate cell death, PMCA-mediated effects on mitochondrial calcium levels could 
determine the sensitivity of MDA-MB-231 cells to death stimuli. This chapter, therefore evaluated 
the potential role of proteins that regulate mitochondrial calcium levels on ionomycin and ABT-263 
cell death responses in MDA-MB-231 breast cancer cells. 
Mitochondrial calcium uptake was attenuated by silencing mitochondria calcium uniporter (MCU) 
expression. Then the consequence of MCU silencing on MDA-MB-231 breast cancer cells death and 
global [Ca2+]CYT was assessed. It was predicted that knocking down MCU expression would reduce 
mitochondrial calcium levels, independently of global [Ca2+]CYT and hence protect MDA-MB-231 
cells against death insults. 
This chapter consists of a manuscript published in the journal Biochemical and Biophysical Research 
Communications, entitled ‘Mitochondrial calcium uniporter silencing potentiates caspase-
independent cell death in MDA-MB-231 breast cancer cells’ [245]. Minor adjustments have been 
made to the original format of the published manuscript to adhere to The University of Queensland 
thesis formatting guidelines.   
The paper presents novel research findings that were predominantly designed and performed by 
myself, Merril C Curry under the supervision of Gregory R Monteith and Sarah J Roberts-Thomson. 
Additional experiments and data performed by Dr. Amelia Peters and Dr. Paraic Kenny were also 
included in the manuscript and have been incorporated into this thesis chapter. Dr. Amelia Peters, a 
fellow laboratory member performed the proliferation studies (Figure 4-2C and D). Dr. Paraic Kenny, 




4.2 Chapter Hypothesis 
 Altered mitochondrial calcium uniporter (MCU) mRNA levels is a feature of specific breast 
cancer molecular subtypes 
 Silencing of the mitochondrial calcium uniporter modulates cell death responses and shapes 
cytoplasmic calcium signals in breast cancer cells  
4.3 Chapter Aims 
 To determine MCU expression levels in clinical breast cancer samples grouped by oestrogen 
receptor status or molecular subtype  
 To assess the function significance of MCU in the context of basal breast cancer using the 
MDA-MB-231 breast cancer cell line   
 To inhibit MCU with specific siRNAs to silence expression of this target gene 
 To study the consequence of MCU silencing on cell death initiated with different stimuli  
 To assess MCU silencing-mediated effects in shaping bulk cytoplasmic calcium signals 
generated using different agents 
4.4 Highlights 
 Some clinical breast cancers are associated with MCU overexpression 
 MCU silencing did not alter cell death initiated with the Bcl-2 inhibitor ABT-263 
 MCU silencing potentiated caspase-independent cell death initiated by ionomycin 





The mitochondrial calcium uniporter (MCU) transports free ionic Ca2+ into the mitochondrial matrix. 
We assessed MCU expression in clinical breast cancer samples using microarray analysis and the 
consequences of MCU silencing in a breast cancer cell line. Our results indicate that oestrogen 
receptor negative and basal-like breast cancers are characterised by elevated levels of MCU. Silencing 
of MCU expression in the basal-like MDA-MB-231 breast cancer cell line produced no change in 
proliferation or cell viability. However, distinct consequences of MCU silencing were seen on cell 
death pathways. Caspase-dependent cell death initiated by the Bcl-2 inhibitor ABT-263 was not 
altered by MCU silencing; whereas caspase-independent cell death induced by the calcium ionophore 
ionomycin was potentiated by MCU silencing. Measurement of cytosolic Ca2+ levels showed that the 
promotion of ionomycin-induced cell death by MCU silencing occurs independently of changes in 
bulk cytosolic Ca2+ levels. This study demonstrates that MCU overexpression is a feature of some 
breast cancers and that MCU overexpression may offer a survival advantage against some cell death 
pathways. MCU inhibitors may be a strategy to increase the effectiveness of therapies that act through 
the induction of caspase-independent cell death pathways in oestrogen receptor negative and basal-





Mitochondria regulate numerous cellular processes and are vital for both sustaining cell survival and 
the initiation of cell death [4, 246]. The uptake of Ca2+ by mitochondria can buffer increases in 
cytosolic free Ca2+ ([Ca2+]CYT) and stimulate specific mitochondrial functions such as ATP synthesis 
[4, 246]. Mitochondrial Ca2+ levels may also influence sensitivity to cell death activators [40, 152]. 
In malignant transformation, remodeling of Ca2+ homeostasis and reprogramming of mitochondrial 
functions could confer cancer cells with a survival advantage and an ability to evade cell death [21, 
247]. Calcium transporters including the voltage-dependent anion-selective channel (VDAC) and the 
mitochondrial Ca2+ uniporter (MCU) [246] participate in mitochondrial Ca2+ uptake and have been 
proposed as potential regulators of cell death [248, 249]. 
Since the molecular identification of MCU [32, 33], several studies have investigated the significance 
of mitochondrial Ca2+ uptake on specific cellular processes through the modulation of MCU 
expression levels. In cardiomyocytes MCU silencing amplifies bulk [Ca2+]CYT and is associated with 
increased contractile responses [250]. In breast cancer cells sustained increases of bulk [Ca2+]CYT are 
associated with the promotion of cell death responses [227]. In the context of breast cancer, a recent 
study in a panel of breast cancer cells lines, including MDA-MB-231 cells, demonstrated that 
mitochondrial-Ca2+ uptake via MCU is critical for tumour growth and metastasis [251]. In this thesis, 
the impact of MCU silencing on cell death was examined in the MDA-MB-231 breast cancer cell 
line. 
MCU has been studied in other cancer types. One recent study identified MCU downregulation as a 
characteristic feature of some human colon and prostate cancer cells [252]. Down-regulation of MCU 
in colon and prostate-derived cancers promotes increased proliferation and bestows resistance to cell 
death stimuli through diminished mitochondrial Ca2+ levels [252]. At the time of these studies there 
had been no published assessment of MCU in the context of breast cancer.  
In this study we assessed MCU expression in clinical breast cancers and evaluated the functional 
significance of MCU silencing on proliferation, cell death pathways and on bulk [Ca2+]CYT in MDA-
MB-231 breast cancer cells. Our results suggest that MCU inhibition may sensitise some breast 




4.7 Materials and Methods 
4.7.1 Analysis of MCU levels in human breast cancer cases 
Gene expression data for 180 human breast cancer cases [253] were obtained from NCBI-GEO 
(Accession GSE3165) and imported into Partek Genomics Suite (version 6.6). MCU (annotated on 
these microarrays as C10orf42) expression was analysed in samples grouped by both oestrogen 
receptors status and PAM50 molecular subtype [254]. 
4.7.2 Cell culture 
Human MDA-MB-231 breast cancer cells (American Type Culture Collection) were grown in high 
glucose DMEM (Sigma Aldrich) supplemented with 10% FBS and 4 mM Lglutamine (Invitrogen) at 
37 °C/5% CO2 in a humidified air incubator. 
4.7.3 Silencing of MCU expression 
MDA-MB-231 cells were transfected as previously described [227] with ON-TARGETplus™ 
SMARTpool siRNAs (Dharmacon), consisting of four pooled siRNA sequences rationally designed 
to minimise off-target effects [195, 196]. The specific siRNAs used in this study were MCU siRNA 
(siMCU, L-015519-02) and the non-targeting control siRNA (siNT, D-001810- 10). For all 
experiments MCU mRNA silencing (>70%) was confirmed at 48 h post-siRNA. 
4.7.4 Quantitative real time RT-PCR 
Quantitative real time RT-PCR was performed as described previously [227]. Briefly, at 48 or 120 h 
post siRNA-transfection total RNA was isolated (RNeasy Plus mini kit; Qiagen), and then reverse 
transcribed (Omniscript RT kit; Qiagen). The cDNA of interest were amplified using the TaqMan 
Fast Universal PCR Master Mix (Applied Biosystems) and TaqMan Gene Expression assays (MCU, 
Hs00293548_m1; 18 S rRNA, 4319413E; Applied Biosystems) under universal cycling conditions 
with a StepOnePlus real time PCR system (Applied Biosystems). MCU mRNA levels were quantified 
by the comparative Ct method as described [197] normalised to 18 S rRNA and presented relative to 




4.7.5 Cell enumeration and S-phase analysis 
MDA-MB-231 cells were transfected with siRNA for 120 h and then cell enumeration and S-phase 
analysis were performed as previously described [255]. Briefly, cells with newly synthesised DNA 
were stained, according to the manufacturer’s instructions using the ClickiT® EdU cell proliferation 
assay (Alexa Fluor 555; Invitrogen). DAPI-stained cell nuclei (400 nM; 90 min) and EdU-positive 
cells were imaged with a 10× objective using an ImageXpress Micro automated epifluorescence 
microscope (Molecular Devices Corporation) [199]. Cell number and percentage of EdU positive 
cells were calculated using the multiwavelength cell scoring application module (MetaXpress 
v3.1.0.83; Molecular Devices). 
4.7.6 Assessment of cell viability 
At 72 h post siRNA-transfection MDA-MB-231 cells were treated with the cell death activators ABT-
263 (Selleckchem), ionomycin (Enzo Life Sciences), or with dimethyl sulfoxide (up to 0.33%) and 
incubated for an additional 48 h. Cell viability was then assessed in non-fixed cells as previously 
reported by evaluating Hoechst 33342 (10 μg/mL; Invitrogen) and propidium iodide (1 μg/mL; 
Invitrogen) staining [227]. Imaging was performed using an ImageXpress Micro automated 
epifluorescence microscope (Molecular Devices Corporation). Criteria for viable and propidium 
iodide positive cells (PI+) were defined as previously described [227]. 
4.7.7 Cytosolic free calcium measurements 
At 72 h post siRNA-transfection MDA-MB-231 breast cancer cells were loaded with either a high 
Ca2+ affinity (Fluo-4AM (4 μM; Molecular Probes)) or a low Ca2+ affinity (Fluo-4FF (4 μM; 
Molecular Probes)) Ca2+ indicator according to published methods [227]. [Ca2+]CYT was then 
monitored using a fluorescence imaging plate reader [198] (Molecular Devices Corporation) as 
previously described [227]. To assess relative [Ca2+]CYT fluorescence was normalised to base-line 
values. 
4.7.8 Statistical analysis 






4.8.1 MCU mRNA levels in clinical breast cancer samples 
Assessment of MCU mRNA levels in a cohort of 180 breast cancer cases [253] showed a significantly 
(P < 0.05; Figure 4-1A) higher level of MCU in oestrogen receptor-negative breast cancers. When 
breast cancers were stratified by molecular subtype the highest levels of MCU were seen in basal-
like breast cancers (P < 0.05; basal-like versus luminal A and B subtypes; Figure 1B), while other 
subtypes expressed intermediated MCU levels (Figure 4-1B). Oestrogen receptor-negative and basal-





Figure 4-1: MCU expression in clinical breast cancers is associated with oestrogen receptor status 
and molecular subtype.  
Relative MCU levels were analysed in human breast cancer cases (n = 180) stratified by (A) oestrogen 
receptor (ER) status and (B) molecular subtype. MCU levels were highest in oestrogen receptor-
negative tumors (P < 0.05, Mann-Whitney test) and showed the strongest enrichment in the basal-
like subtype (P < 0.05; basal-like versus Luminal A and B, Kruskall-Wallis test with Dunn’s post-




4.8.2 Effects of MCU silencing on proliferation and cell viability in MDA-MB-231 breast cancer cells 
To assess the possible role of MCU overexpression in breast cancer, we used specific siRNAs to 
silence MCU expression in basal-like MDA-MB-231 breast cancer cells [240]. Compared to the siNT 
control, cells transfected with siMCU showed a significant (P < 0.05) decrease in MCU mRNA levels 
at 48 h (Figure 4-2A) and 120 h (Figure 4-2B) post-siRNA. Using this model, we assessed the effects 
of MCU knockdown on proliferation and cell viability.  
Effects of MCU silencing on cell proliferation were evaluated by cell enumeration and S-phase 
analysis (EdU staining). MCU silencing did not significantly alter cell number (Figure 4-2C), or the 
percentage of cells in S-phase (EdU positive; Figure 4-2D) compared to the siNT control. Cell 
viability was also quantified; MCU silencing had no significant effect on the percentage of viable 






Figure 4-2: MCU silencing in MDA-MB-231 cells and the effects of silencing on proliferation and cell 
viability.  
MCU was silenced in MDA-MB-231 cells using siRNA and the effects on cell number, S-phase and cell 
viability were compared to the siNT control. Relative MCU mRNA levels at (A) 48 h and (B) 120 h post-
transfection with siMCU or siNT. Effects of MCU knockdown on (C) average cell number, (D) 
percentage S-phase (EdU-positive cells) and (G) percentage viable cells. Bar graphs show the mean ± 
S.D obtained from three independent experiments (n = 3) performed in triplicate. Dot plots show changes 
in cell viability with either (E) siNT or (F) siMCU for 10,000 cells randomly selected from three 
independent experiments (n = 3) performed in triplicate wells. *P < 0.05, paired two-tailed t test. 
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4.8.3 MCU silencing sensitises MDA-MB-231 breast cancer cells to ionomycin-mediated cell death 
To analyse whether MCU silencing regulates breast cancer cell responses to death activators, siRNA-
transfected MDA-MB-231 cells were treated with the Ca2+ ionophore ionomycin to initiate caspase-
independent cell death [227]. Compared to the siNT control MCU silencing potentiated sub-maximal 
ionomycin (3 μM)-mediated cell death, with a significant (P < 0.05) reduction in cell viability and a 
marked (P < 0.05) increase in the proportion of propidium iodide positive cells (Figure 4-3A). 
Silencing of MCU did not alter cell viability at a higher ionomycin concentration (10 μM) compared 
to the siNT control (Figure 4-3B). These data suggest MCU silencing sensitises MDA-MB-231 cells 
to caspase-independent cell death initiated with ionomycin. 
4.8.4 MCU silencing does not modulate ABT-263-mediated MDA-MB-231 breast cancer cell death 
The Bcl-2 inhibitor ABT-263 was used to address the consequence of MCU silencing on caspase-
dependent cell death in the MDA-MB-231 breast cancer cell line [227]. Compared with //the siNT 
control, MCU silencing exerted no effect on cell death initiated at either the sub-maximal (3 μM; 
Figure 4-3C) or high (10 μM; Figure 4-3D) ABT-263 concentrations. This suggests that MCU 







Figure 4-3: Consequences of MCU silencing on ionomycin- and ABT-263-initiated cell death in MDA-
MB-231 cells.  
MCU was silenced in MDA-MB-231 cells using siRNA and then cells were treated with (A) 3 µM 
ionomycin, (B) 10 µM ionomycin, (C) 3 µM ABT-263 or with (D) 10 µM ABT-263 for 48 h prior to 
cell death assessment. Bar graphs show mean ± S.D of the proportion of viable and propidium iodide 
positive (PI+) cells in siMCU and siNT transfected cells. Data were obtained from three independent 





4.8.5 Effects of MCU silencing on increases in bulk cytosolic calcium 
To assess whether MCU silencing modified the nature of bulk [Ca2+]CYT increases, we challenged 
siRNA-transfected MDA-MB-231 breast cancer cells with different initiators of [Ca2+]CYT increases. 
Moderate increases in bulk [Ca2+]CYT were induced with the sarcoendoplasmic reticulum Ca
2+-
ATPase (SERCA) inhibitor cyclopiazonic acid (CPA; 10 μM) or the protease activated receptor 
activator trypsin (0.1 μM) under Ca2+-free conditions. Compared with the siNT control, silencing of 
MCU did not alter either CPA (Figure 4-4A) or trypsin (Figure 4-4C) Ca2+ responses, with no 
significant difference detected for area under the curve (Figure 4-4B and D) or other Ca2+ transient 
parameters such as peak [Ca2+]CYT and half peak decay time (data not shown). 
A role for MCU in shaping Ca2+ signals of higher magnitude was evaluated in the presence of 
extracellular Ca2+ (2 mM) using the Ca2+ ionophore ionomycin. Assessment of [Ca2+]CYT with the 
low affinity Ca2+ indicator Fluo-4FF, showed that MCU silencing compared to the siNT control had 
no major effects on bulk [Ca2+]CYT increases, at either sub-maximal (3 μM; Figure 4-4E-F) or high 
(10 μM; Figure 4-4G-H) ionomycin concentrations. Collectively, these findings demonstrate that 









Figure 4-4: Effect of MCU silencing on bulk [Ca2+]CYT increases stimulated by various initiators of 
[Ca2+]CYT increases.  
(A) CPA (10 μM)-mediated and (C) trypsin (0.1 μM)-induced [Ca2+]CYT transients measured with the 
Ca2+ indicator Fluo-4AM after transfection with siMCU or siNT in the presence of extracellular 
BAPTA (100 μM). (E) 3 μM ionomycin and (G) 10 μM ionomycin [Ca2+]CYT transients recorded 
using the Ca2+ indicator Fluo-4FF in cells transfected with siNT or siMCU. Bar graphs show the mean 
± S.D for the area under the curve calculated for the (B) 10 μM CPA, (D) 0.1 μM trypsin, (F) 3 μM 
ionomycin and (H) 10 μM ionomycin [Ca2+]CYT increases. Ca2+ traces represent relative mean 
fluorescence. All data were obtained from three independent experiments (n = 3) performed in 




A previous study identified MCU downregulation in prostate and colon-derived cancers [252], here 
we present data showing that MCU is upregulated in some clinical breast cancer subtypes. MCU was 
most highly expressed in oestrogen receptor-negative and basal-like breast cancers both of which are 
associated with a poor prognosis [167, 170]. To understand the implication of MCU overexpression 
in breast cancer, we assessed the functional consequences of MCU silencing on proliferation, cell 
death and bulk [Ca2+]CYT in the basal-like MDA-MB-231 breast cancer cell line. 
Our silencing studies in MDA-MB-231 cells showed MCU knockdown had no effect on proliferation 
or cell viability. However, assessment of MCU knockdown on cell death initiated by ABT-263 and 
ionomycin defined a distinct role for MCU in the regulation of caspase-independent and -dependent 
cell death pathways, respectively. MCU silencing did not affect ABT-263-mediated cell death, but 
acted as a sensitiser of cell death initiated with ionomycin. MCU silencing attenuates mitochondrial 
Ca2+ uptake [32, 33] and reduced mitochondrial Ca2+ levels act to suppress cell death in a variety of 
malignant cell lines, including those derived from the cervix [152] central nervous system [256], head 
and neck [257] and lymph [258] tissues. We therefore hypothesised that MCU knockdown in MDA-
MB-231 breast cancer cells would also protect from death insults. However, MCU knockdown did 
not protect against ABT-263-induced cell death, and potentiated ionomycin-initiated cell death.  
Alterations in bulk [Ca2+]CYT signals were examined as a potential mechanism of MCU silencing-
mediated promotion of ionomycin-initiated cell death. In cardiomyocytes MCU silencing amplifies 
cytosolic Ca2+ signals [250] and we have recently shown sustained increases of bulk [Ca2+]CYT are 
associated with the promotion of ionomycin-mediated MDA-MB-231 cell death [227]. However, our 
assessment of bulk [Ca2+]CYT showed no major changes upon MCU knockdown on Ca
2+ signals 
stimulated with CPA, trypsin or ionomycin. These data suggest that MCU does not significantly 
contribute in buffering global cytosolic free Ca2+; therefore increases in bulk [Ca2+]CYT are unlikely 
to explain the promotion of ionomycin-initiated cell death upon MCU silencing. 
The ability of MCU silencing to sensitise MDA-MB-231 cells to ionomycin-mediated cell death 
could be due to diminished mitochondrial Ca2+ uptake and alterations in the autophagy survival 
pathway, as the specific MCU inhibitor Ru360 regulates autophagy in HEK293 and DT40 cells [259]. 
Another mechanism may involve alterations in localised Ca2+ signals within specialised signaling 
domains at the endoplasmic reticulum-mitochondrial interface, known as mitochondrial-associated-
membranes (MAMs) [260]. A recent study investigated reduced mitochondrial Ca2+ uptake through 
knockdown of the MAM-enriched calcium transporter, VDAC1 [261]. VDAC1 silencing potentiates 
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the response of human-derived HeLa cervical cancer cells to death activators without affecting bulk 
[Ca2+]CYT, this sensitisation was not dependent on diminished mitochondrial Ca
2+ levels [261]. 
Localised Ca2+ signals possibly within MAM domains may represent another regulatory site for Ca2+-
dependent death signals in breast cancer cells and along with MCU-mediated regulation of autophagy 
requires further investigation. 
In this report, we have identified MCU overexpression in some clinical breast cancers, in particular 
those subtypes associated with a poor prognosis (oestrogen receptor negative and basal-like). MCU 
silencing in the basal-like MDA-MB-231 breast cancer cell line promoted ionomycin-initiated but 
not ABT-263-mediated cell death. MCU inhibitors may therefore represent novel therapies for some 
breast cancers by potentiating some caspase-independent cell death mechanisms. 
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4.11 Additional experiments relevant to chapter four, but not included in the manuscript 
4.11.1 Introduction 
Extending upon the studies published in the Journal of Biochemical and Biophysical Research 
Communications [245], the consequence of MCU silencing on ATP calcium responses and on store-
operated calcium entry, along with MCU-mediated effects on ceramide cell death was also assessed. 
4.11.2 Materials and methods 
4.11.2.1 Cell culture 
Human MDA-MB-231 breast cancer cells were cultured as described in section 4.7.2, page 130. 
4.11.2.2 Silencing of MCU expression 
MCU expression was silenced by the methods detailed in section 4.7.3, page 130. 
4.11.2.3 Quantitative real time RT-PCR 
MCU mRNA silencing (>70%) was confirmed for all experiments, as detailed in section 4.7.4, page 
130 using quantitative real time RT-PCR.  
4.11.2.4 Assessment of cell viability 
At 72 h post siRNA-transfected MDA-MB-231 cells were treated with ceramide (Sigma Aldrich), or 
with dimethyl sulfoxide (up to 0.33%) and incubated for 48 h. Assessment was then performed 
according to the method in section 4.7.6, page 131. 
4.11.2.5 Cytosolic free calcium measurements 
[Ca2+]CYT was assessed as described in section 4.7.7, page 131. 
4.11.2.6 Statistical analysis 




4.11.3 Results and discussion 
4.11.3.1 MCU silencing-mediated regulation of MDA-MB-231 breast cancer cell death initiated with ceramide 
MCU silencing-mediated effects on ceramide cell death were examined.  In MDA-MB-231 breast 
cancer cells, ceramide induced cell death at sub-maximum (30 μM; Figure 4-5A) and maximum (10 
μM; Figure 4-5B) concentrations, both of which were not altered (P > 0.05) upon MCU silencing 
compared to the siNT control.  
In these thesis studies, the lack of effect detected by MCU silencing on ceramide (Figure 4-5) and 
ABT-263 (section 4.8.4, page 136) cell death responses is consistent with other reports. Hall et al. 
[262] report by silencing and overexpression techniques, although a regulator of mitochondrial 
calcium levels, MCU-mediated Ca2+ uptake does not modulate MDA-MB-231 cell death initiated by 
various stress protocols and the lipid mediator ceramide [262]. Another study in multiple breast 
cancer cells lines including MDA-MB-468, BT-549 and MDA-MB-231 cells, demonstrates that 
mitochondrial-Ca2+ uptake via MCU, although not crucial for cell death, is instrumental for other 
cancer-relevant pathways such as tumour growth and metastasis [251].  
In this thesis work, MUC silencing had no effect on ABT-263 cell death, however, cell death initiated 
with ionomycin was augmented by MCU silencing.  The mechanism associated with siMCU-
mediated sensitisation of ionomycin-induced cell death is unclear (section 4.8.3, page 136), however, 
this effect may involve changes in local Ca2+ signals within cytoplasmic domains or even changes in 
[Ca2+]ER, which are probably undetected in the measurements of bulk [Ca
2+]CYT [151, 261]. Future 
assessment of Ca2+ signals in the mitochondria and in the endoplasmic reticulum would provide a 





Figure 4-5: Consequences of MCU silencing on ceramide-initiated cell death in MDA-MB-231 cells. 
MCU was silenced in MDA-MB-231 cells using specific siRNAs, and then cells were treated with either 
(A) 30 µM ceramide, or (B) 100 µM ceramide for 48 h prior to cell death assessment. Bar graphs are 
mean ± S.D, and show the proportion of viable, propidium iodide positive (PI+) and apoptotic cells in 
siMCU and siNT transfected cells. Data were obtained from three independent experiments (n = 3) 




4.11.3.2 Effects of MCU silencing on cytoplasmic free calcium signals associated with ATP  
The ability of MCU silencing to modify purinergic receptor agonist ATP calcium signals was tested. 
siRNA-transfected MDA-MB-231 breast cancer cells were treated with ATP (100 μM) in nominal 
free Ca2+ physiological salt solution containing BAPTA (100 µM). Compared with the siNT control, 
silencing MCU produced very subtle, but statistically significant (P < 0.05) effects on the calcium 
transient parameters area under the curve (Figure 4-6B) and half peak decay time (Figure 4-6C). 
Although siMCU had no effect (P > 0.05) on peak amplitude (Figure 4-6D), the ability for siMCU to 
modestly increase the area under the curve and delay the half peak time highlights the potential for 
MCU-mediated Ca2+ influx to fine-tune cytoplasmic Ca2+ signals. Future studies could assess the 
functional significance on such fine tuning (e.g. gene transcription).
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Figure 4-6: Effect of MCU silencing on ATP-mediated [Ca2+]CYT increases in MDA-MB-231 breast cancer cells.  
Cells transfected with siMCU or siNT were challenged with (A) ATP (100 μM) and [Ca2+]CYT were measured in the presence of extracellular BAPTA 
(100 μM) in nominal free Ca2+. Bar graphs show the mean ± S.D for the calcium transient parameters (B) area under the curve (C) half peak decay time 
and (D) peak amplitude associated with the ATP calcium responses. Ca2+ traces represent relative mean fluorescence. All data were obtained from three 
independent experiments (n = 3) performed in triplicate. *P < 0.05, paired two-tailed t test. 
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4.11.3.3 Effects of MCU silencing on receptor operated and store operated calcium entry in MDA-MB-231 
breast cancer cells 
The ability for mitochondria Ca2+-uptake to buffer cytoplasmic Ca2+ signals including Ca2+ influx via 
store operated calcium entry (SOCE) is reported [246, 263]. Mitochondrial Ca2+ uptake, in addition 
to regulating mitochondria function, can therefore shape bulk [Ca2+]CYT signals [4, 246]. In this thesis, 
to examine whether MCU silencing modified bulk [Ca2+]CYT increases associated with ROCE and 
SOCE, siRNA-transfected MDA-MB-231 cells were treated with either CPA (10 μM), trypsin (0.1 
μM) or ATP (100 µM), in nominal free Ca2+ physiological salt solution containing BAPTA (100 µM) 
(Figure 4-7). After the initial [Ca2+]CYT increases returned to baseline, a second phase of [Ca
2+]CYT 
increase was monitored following the re-addition of external Ca2+ (Figure 4-7A, C and E). MCU 
silencing-mediated effects on ROCE (Figure 4-7D and E) and on SOCE (Figure 4-7B) were 
determined by assessment of peak ratio derived by dividing the second peak amplitude with the first 
peak amplitude [29, 234]. 
MCU knockdown had no effect on the peak ratio associated with CPA (Figure 4-7B) or trypsin 
(Figure 4-7D). However, siMCU produced a subtle, but statistically significant (P < 0.05) increase in 
the peak ratio (Figure 4-7F) associated with the purinergic receptor agonist ATP. Although MCU is 
not a major regulator of bulk [Ca2+]CYT these data identify that MCU can fine-tune cytoplasmic 
calcium signals for some stimuli. Future investigations are required to ascertain the ability of MCU 
silencing to shape those Ca2+ signals associated with SOCE within localised regions of MDA-MB-







Figure 4-7: Consequence of MCU silencing on store-operated, ATP and trypsin stimulated calcium entry 
in MDA-MB-231 breast cancer cells 
In the presence of external BAPTA (100 μM) and under nominal free Ca2+ conditions, [Ca2+]CYT increases 
were measured in MDA-MB-231 cells transfected with siMCU or siNT and challenged with (A) CPA 
(100 μM), (C) trypsin (0.1 µM) or (E) ATP (100 µM). After the initial phase of Ca2+ influx returned to 
baseline, cells were treated with external Ca2+ to stimulate a second phase of Ca2+ influx. (B, D and F) 
Bar graphs show the mean ± S.D for the calcium transient parameter peak ratio associated with (B) CPA, 
(D) trypsin and (F) ATP Ca2+ signals. Ca2+ traces are relative mean fluorescence. All data were obtained 
from three independent experiments (n = 3) performed in triplicate. *P < 0.05, paired two-tailed t test. 
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4.12 Chapter Summary 
Forming the main content of this chapter was the manuscript published in the Journal of Biochemical 
Research Communications. High MCU mRNA levels were detected in oestrogen receptor-negative 
and basal-like breast cancer subtypes. The functional significance of MCU expression on cell death 
was examined by assessing the consequence of MCU silencing on global calcium signals and on cell 
death responses in the basal-like MDA-MB-231 breast cancer cell line.  
No measurable effect on cell proliferation or viability was detected with MCU knockdown. 
Therefore, MCU silencing-mediated effects on cell death initiated with the Bcl-2 inhibitor (ABT-
263), ionomycin and ceramide were examined. MCU silencing had no effect on cell death triggered 
by either the Bcl-2 inhibitor ABT-263 or the lipid mediator ceramide. These data show that MCU-
calcium uptake may not be a critical factor that determines MDA-MB-231 cell responsiveness to 
some death stimuli. 
Surprisingly, ionomycin initiated caspase-independent cell death was augmented by MCU silencing. 
Reduced calcium uptake via MCU may therefore, indirectly promote cell death through effects on 
global [Ca2+]CYT. Assessment of bulk [Ca
2+]CYT increases generated with different agents, illustrated 
that MCU-silencing is not a predominant regulator of bulk [Ca2+]CYT in MDA-MB-231 breast cancer 
cells. Only modest effects on the calcium transient parameters associated with ATP calcium signals 
were detected.  
Although unclear, MCU silencing-mediated promotion of ionomycin cell death could depend on fine-
tuning localised Ca2+ signals within [Ca2+] micro-domains.  Since the calcium assays in this thesis 
were designed to monitor bulk [Ca2+]CYT, the effect of MCU silencing on local calcium signals were 
probably overlooked. Assessment of MCU silencing effects on local calcium signals, and on other 
events such as NFκB transcription factor activity, which are influenced by calcium signal oscillation 
frequency [263], requires further investigation in MDA-MB-231 cells. 
These initial studies provide evidence that in aggressive subtypes of breast cancer, only some cell 
death responses (e.g. ionomycin-induced cell death) are promoted by MCU silencing, and this 
promotion is most likely to involve effects on localised Ca2+ signals within subcellular-domains, 





Chapter 5 Overall Discussion and Conclusions 
PMCA calcium pumps are widely distributed throughout the body, and based on their molecular 
features are predicted to regulate innumerable processes in different cell types. The work in this thesis 
describes the role of PMCA isoforms in the regulation of cell death in the human MDA-MB-231 
breast cancer cell line. In addition to cell death, the ability of PMCA isoforms in shaping Ca2+ signals 
generated using a panel of Ca2+ mobilising agents was characterised in this thesis. 
Chapter Two demonstrated that PMCA1 and PMCA4 distinctly shape Ca2+ signals and differentially 
regulate cell death. PMCA1 was identified as a major regulator of global [Ca2+]CYT. PMCA1 silencing 
promoted ionomycin-initiated cell death and was associated [Ca2+]CYT increases. The consequences 
of PMCA1 silencing, were in contrast to those effects identified with PMCA4 silencing. PMCA4 did 
not significantly regulate global [Ca2+]CYT signals and PMCA4 silencing did not promote ionomycin-
initiated cell death. Silencing of PMCA4, did however promote Bcl-2 inhibitor-initiated apoptosis.  
The ability of PMCA4 silencing to regulate Bcl-2 inhibitor-mediated cell death was the subject of 
further investigation. Effects of PMCA1 or PMCA4 silencing on NFκB nuclear translocation was 
examined and the effect of NFκB inhibition was also assessed in MDA-MB-231 cells.  NFκB nuclear 
translocation, although unaffected by PMCA1 silencing, was attenuated by PMCA4 silencing. In 
addition, the ability for the NFκB-inhibitor IMD-0354 to mimic the effect of PMCA4 silencing in the 
promotion of Bcl-2 inhibitor cell apoptosis was identified. These results indicate that PMCA4-
mediated modulation of breast cancer cell death, rather than acting through global [Ca2+]CYT 
increases, could involve the regulation of NFκB transcription factor activity via changes in local 
calcium signals. 
Additional Ca2+ studies examined in more depth, the consequence of PMCA1 silencing on GPCR-
linked Ca2+ signals when SERCA activity was pharmacologically blocked with CPA. These set of 
experiments identify a critical role for PMCA1-mediated Ca2+ efflux during P2Y receptor activation. 
The ability of SERCA activity to compensate for impaired PMCA1 efflux during PAR receptor 
activation became apparent through assessment of ROCE associated with trypsin-mediated Ca2+ 
signalling. PMCA1 silencing reduced ROCE stimulated with trypsin, and this could be the 
consequence of increased [Ca2+]ER via increased SERCA activity. However, future assessment of 
[Ca2+]ER under these same experimental conditions are required to examine this possibility. 
Chapter three extended these thesis studies to PMCA2, and assessed the potential of PMCA2-
silencing to activate MDA-MB-231 cell death and augment intracellular Ca2+ signals. Previous 
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reports indicate that PMCA2-mediated regulation of breast cancer cell death involves changes in 
global Ca2+ signals. However, in thesis studies, PMCA2 was shown to be expressed at relatively low 
levels in MDA-MB-231 breast cancer cells, and although not a major regulator of global [Ca2+]CYT, 
PMCA2-mediated silencing promoted Bcl-2 inhibitor apoptosis. Analogous to PMCA4 silencing in 
this cell line, PMCA2 silencing is probably promoting Bcl-2 inhibitior apoptosis via local calcium 
signals, and likely associated with effects on the Ca2+ dependent transcription factor NFκB, although 
this requires direct assessment in future studies.  
Mitochondrial Ca2+ signals can determine cellular sensitivity to death stimuli. Because [Ca2+]MIT 
could be regulated by PMCA isoforms, PMCA-mediated regulation of cell death identified in thesis 
chapters two and three could involve changes in [Ca2+]MIT.  Therefore, in chapter four of this thesis I 
examined the ability of MCU silencing to protect against ABT-263 or ionomycin MDA-MB-231 cell 
death. Surprisingly, MCU silencing had no effect on Bcl-2 inhibitor apoptosis, yet promoted 
ionomycin-mediated cell death. Although future studies are required to confirm the role of [Ca2+]MIT 
levels under these experimental conditions, these initial studies indicate that MCU-mediated calcium 
uptake into the mitochondria does not modulate MDA-MB-231 cell death initiated via Bcl-2 
inhibition. Therefore, the promotion of Bcl-2 inhibition-initiated apoptosis in this breast cancer cell 
line by PMCA4 and PMCA2 silencing may be independent of [Ca2+]MIT.  
In summary, these studies provide evidence that PMCA isoforms expressed in the same cell can carry 
out very different functions. Even though PMCA1 appears to be the so-called “housekeeping” 
isoform in MDA-MB-231 cells, this isoform can still exert very specific effects on GPCR-linked 
calcium signals. Therefore, PMCA1 is equipped with the capacity to do more than simply efflux Ca2+, 
PMCA1 may be able to make specific contributions to cellular signalling. To fully understand the 
translational impact of these silencing studies in the context of breast cancer, however, future studies 
with PMCA specific inhibitors are essential. Until recently, the lack of specific PMCA inhibitors has 
been a limitation in the field of PMCA research. The identification of a potent PMCA4 inhibitor 
aurintricarboxylic [264] and the ability of this drug-like molecule to inhibit and reverse cardiac 
hypertrophy in mice [265] provides clear evidence that PMCAs are emerging drug targets [266]. 
In MDA-MB-231 cells, PMCA4 and PMCA2 are both expressed at lower levels compared with the 
PMCA1 isoform. However, these isoforms should not be considered redundant just because they do 
not significantly shape global calcium signals in this cell line. Instead, PMCA4 and PMCA2 in this 
cell line appear to play an important role in regulating cell death via more subtle effects on local 
calcium signals or other mechanisms independent of global [Ca2+]CYT levels. As indicated by the 
work in this thesis, PMCA2 or PMCA4 inhibitors may represent a strategy to sensitise some breast 
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cancer subtypes to anti-cancer therapies that work via the inhibition of Bcl-2. This approach may be 
especially relevant in the context of   basal-like subtypes of cancer that overlap with triple negative 
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